Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment

W Nathaniel Brennen, Samuel R Denmeade and John T Isaacs

Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB-I, Room 1M44, Baltimore, Maryland 21287, USA

Correspondence should be addressed to J T Isaacs

Email
isaacjo@jhmi.edu

Abstract

Mesenchymal stem cells (MSCs) have an inherent tropism for sites of inflammation, which are frequently present in sites of cancer, including prostatic lesions. MSCs have been defined as CD73/CD90/CD105 triple-positive cells in the absence of hematopoietic lineage markers with the ability to differentiate into multiple mesodermal lineages, including osteoblasts, adipocytes, and chondrocytes. Our group has previously demonstrated that MSCs represent between 0.01 and 1.1% of the total cells present in human prostatectomy tissue. In addition to their multi-lineage differentiation potential, MSCs are immunoprivileged in nature and have a range of immunomodulatory effects on both the innate and adaptive arms of the immune system. MSCs have been detected in an increasing array of tissues, and evidence suggests that they are likely present in perivascular niches throughout the body. These observations suggest that MSCs represent critical mediators of the overall immune response during physiological homeostasis and likely contribute to pathophysiological conditions as well. Chronic inflammation has been suggested as an initiating event and progression factor in prostate carcinogenesis, a process in which the immunosuppressive properties of MSCs may play a role. MSCs have also been shown to influence malignant progression through a variety of other mechanisms, including effects on tumor proliferation, angiogenesis, survival, and metastasis. Additionally, human bone marrow-derived MSCs have been shown to traffic to human prostate cancer xenografts in immunocompromised murine hosts. The trafficking properties and immunoprivileged status of MSCs suggest that they can be exploited as an allogeneic cell-based vector to deliver cytotoxic or diagnostic agents for therapy.

Key Words

- ▶ mesenchymal stem cell
- ▶ MSC
- ▶ inflammation
- ▶ prostate cancer
- ▶ multipotent stromal cell

Endocrine-Related Cancer
(2013) 20, R269–R290

Introduction

The prostate is the most common organ in the human body to undergo neoplastic transformation when accounting for both benign and malignant lesions. Pathological benign prostatic hyperplasia (BPH) affects >50% of men over the age of 50 years with nonclinical incidence representing a far greater number (Berry *et al.*

1984). Similarly, autopsy studies have demonstrated histological prostate cancer in as many as 50% of men by the age of 50 years with a linear increase in incidence for each subsequent decade of life (Delongchamps *et al.* 2006). The etiology of BPH and prostate cancer is unclear; however, chronic inflammation has been suggested as a

contributing factor in both (Nelson *et al.* 2003, De Marzo *et al.* 2007, Kramer *et al.* 2007, De Nunzio *et al.* 2011, Sfanos & De Marzo 2012). The prostate, by virtue of its anatomical nature, is among a subset of tissues with a direct route of access to the external environment. Due to this exposure, the prostate routinely comes into contact with potentially infectious agents and frequently contains focal sites of inflammation. Though inflammation is commonly present, external pathogens often cannot be identified within these lesions (De Nunzio *et al.* 2011), suggesting that the inflammatory response persists after the pathogen is cleared or non-pathogenic stimuli are responsible. Other causative agents of prostatic inflammation include dietary and hormonal factors, in addition to chemical and physical irritations resulting from urine reflux and corpora amylacea respectively (De Marzo *et al.* 2007, De Nunzio *et al.* 2011). Furthermore, damage to epithelial cells and glandular structure as a result of these factors can contribute to altered antigen processing and presentation, which can generate an autoimmune response if these peptides are not recognized as 'self' or tolerance is broken (De Nunzio *et al.* 2011, Jackson *et al.* 2012). Independent of the origin, a chronic inflammatory state can arise as made evident by an age-associated persistent presence of an infiltrating leukocyte population (Kramer *et al.* 2007, Nickel *et al.* 2008).

A heuristic model of prostate carcinogenesis suggests that prostate cancer progresses through proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia (PIN) precursor lesions prior to malignant transformation (Fig. 1). PIA is defined as focal sites of hyperproliferative epithelial atrophy that are frequently associated with inflammation (De Marzo *et al.* 1999, Nelson *et al.* 2003). PIA is often adjacent to areas of PIN, which are characterized by intraductal cellular proliferation with no evidence of basement membrane and stromal invasion (Clouston & Bolton 2012). During both normal physiological processes and pathophysiological states, dynamic interactions initiated by paracrine mediators occur between the epithelium and cells normally restricted to the stroma, including smooth muscle cells, fibroblasts, bone marrow-derived mesenchymal stem cells (BM-MSCs), and various inflammatory cells. The latter of these have not only been associated with the initiation of prostate cancer but have also been suggested as potential drivers of its progression by virtue of DNA-damaging reactive oxygen species, a variety of immunosuppressive mechanisms, and the secretion of mitogenic and pro-angiogenic cytokines (Nelson *et al.* 2003, De Marzo *et al.* 2007, Sfanos & De Marzo 2012). Once

the cancer cells have penetrated the basement membrane, they have direct contact with cells that were previously restricted to paracrine interactions, in addition to direct access to growth factors, survival signals, pro-invasion molecules, and extracellular matrix proteins. In total, these are collectively known as the tumor microenvironment and can have profound effects on cancer progression, malignancy, and therapeutic outcome (Cunha *et al.* 2003, Bissell & Hines 2011, Dayyani *et al.* 2011, Hanahan & Weinberg 2011, Brennen *et al.* 2012, Correia & Bissell 2012).

Chemokines, such as CXCL12 (SDF-1), CCL5 (RANTES), and CCL2 (MCP-1) and the rest of the inflammation-associated secretory milieu, have been shown to recruit MSCs to these sites as a result of the high expression of chemokine and cytokine receptors on their surface (Spaeth *et al.* 2008). Recently, our group has demonstrated that MSCs are not only present at sites of human prostate cancer but also represent 0.01–1.1% of the total cells present in human prostatectomy tissue cores (Brennen *et al.* 2013). MSCs have been shown to be critical mediators of the overall immune response (Caplan 2009, Newman *et al.* 2009, English & Mahon 2011) and, therefore, may contribute to carcinogenesis through a variety of mechanisms, including stimulation of proliferation, angiogenesis, and metastasis, in addition to their immunosuppressive properties (Bergfeld & DeClerck 2010, Klopp *et al.* 2011). These latter properties may be particularly relevant in tumor progression as the cancer cells must escape immune surveillance and clearance to reach their full malignant potential (Fig. 1). Perhaps more importantly, the tumor trafficking properties of MSCs suggest that they could be used to deliver therapeutic or diagnostic agents to sites of prostate cancer, both primary and secondary lesions (Brennen *et al.* 2013).

MSCs: mesenchymal stem cells

Recently, there has been an increasing appreciation for the role of MSCs, also known as multipotent stromal cells, in modulating both innate and adaptive immune responses. These cells were initially characterized by Friedenstein *et al.* (1970) as clonogenic cells in culture that were multipotent stromal precursors. Throughout much of the early literature, these cells were referred to as colony-forming unit fibroblasts or CFU-Fs (Friedenstein *et al.* 1976), until Caplan proposed the term 'Mesenchymal Stem Cells' in 1991 (Caplan 1991). Over the ensuing years, there has been much debate regarding the appropriateness of this terminology (Horwitz *et al.* 2005, Bianco *et al.* 2008,

Figure 1

MSCs in the normal and malignant prostate. A heuristic model of prostate carcinogenesis suggests that the normal gland progresses through proliferative inflammatory atrophy (PIA) and prostatic intraepithelial neoplasia (PIN) stages on its path to malignant transformation. MSCs likely have significant immunomodulatory roles not only in the normal prostate but throughout all stages of prostate cancer tumorigenesis and progression

as well. These properties are mediated through the secretion of various chemokines (SDF1, CCL2, and CCL5), cytokines (IL4, IL6, IL8, IL10, M-CSF, IFN- γ , and TNF α) and other bioactive signaling molecules (TGF- β , PG, and IDO) that can indirectly affect carcinogenesis through leukocyte intermediates but also through direct effects on the cancer cells themselves. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-13-0151>.

Ho *et al.* 2008, Nombela-Arrieta *et al.* 2011); however, this continues to be the accepted consensus in the literature.

The International Society for Cell Therapy has minimally defined MSCs as plastic-adhering multipotent cells of fibroblastoid morphology with the ability to differentiate into cells of the osteogenic, adipogenic, and chondrogenic lineages (Pittenger *et al.* 1999, Dominici *et al.* 2006). MSCs have been further defined based upon the expression of CD90 (Thy-1), CD105 (endoglin), and CD73 (5'-nucleotidase) in the absence of hematopoietic lineage markers, including CD45, CD34, CD14 or CD11b, CD79 α or CD19, and HLA-DR expression (Dominici *et al.* 2006). Although some are more controversial than others, there is also evidence to suggest that MSCs can differentiate into myocytes (Wakitani *et al.* 1995, Crisan *et al.* 2008), fibroblasts (Lee *et al.* 2010), pericytes (Hirschi & D'Amore 1996, Crisan *et al.* 2008), and neurons (Woodbury *et al.* 2000, Hofstetter *et al.* 2002, Bertani

et al. 2005, Krampera *et al.* 2007, Phinney & Prockop 2007), although neuronal differentiation appears to be correlated with the age of the donor (Hermann *et al.* 2010, Brohlin *et al.* 2012). The number of MSCs in an individual declines with age, as demonstrated by a 100-fold decrease in the ability of nucleated marrow cells to form colonies (CFU-F), from ~ 1 in 10^4 in newborns to ~ 1 in 10^6 in the elderly (Caplan 2009). Furthermore, while MSCs are generally thought to be derived from the mesoderm (Vodyanik *et al.* 2010), there is an initial wave of neuroectodermal MSCs during embryogenesis that arise from the neural crest (Takashima *et al.* 2007, Morikawa *et al.* 2009). Additional evidence suggests that the percentage of MSCs derived from the neural crest declines with age (Takashima *et al.* 2007), which may explain the loss of neuronal differentiation potential observed in MSCs derived from older donors. Additionally, the mesenchymoangioblast was also recently identified as a

mesoderm-derived precursor able to generate both MSCs and endothelial cells (Vodyanik *et al.* 2010). MSCs have also been isolated from numerous peripheral tissues, including fat, skin, dental pulp, and pancreas (Zuk *et al.* 2002, da Silva Meirelles *et al.* 2006, Zhang *et al.* 2006, Davani *et al.* 2007, Crisan *et al.* 2008, Blasi *et al.* 2011) and are likely present in all tissues at low levels as part of a homeostatic surveillance mechanism.

MSCs: tissue of origin

MSCs isolated from these peripheral tissues are frequently thought of as equivalent to those derived from bone marrow due to significantly overlapping properties; however, there is accumulating evidence to suggest that there are differences between these populations, including their expression profiles (Panepucci *et al.* 2004, Wagner *et al.* 2005, Park *et al.* 2007, Noel *et al.* 2008, Jansen *et al.* 2010, Strioga *et al.* 2012) and differentiation potential (Sakaguchi *et al.* 2005, Musina *et al.* 2006, Strioga *et al.* 2012). These differences may reflect a 'memory', epigenetic or otherwise, associated with distinct signaling events and cellular interactions that occur between MSCs and unique microenvironments. For example, multiple studies have shown that MSCs isolated from fat tissue, or adipose-derived stem cells (ADSCs), have an increased propensity to form adipocytes relative to those derived from bone marrow (Sakaguchi *et al.* 2005, Musina *et al.* 2006). Both synovium- and BM-MSCs seem to have a greater ability to generate chondrocytes than ADSCs (Sakaguchi *et al.* 2005, Afizah *et al.* 2007). Additionally, ADSCs generate osteoblasts with less efficiency relative to their bone marrow-derived counterparts (Sakaguchi *et al.* 2005). However, other studies have shown that both BM-MSCs and ADSCs have equal osteoblast and adipocyte differentiation potential (De Ugarte *et al.* 2003, Krampera *et al.* 2007, Noel *et al.* 2008, Pachon-Pena *et al.* 2011). Our own studies suggest that MSCs from the prostates of young, healthy men selectively lose their adipocyte differentiation ability (W N Brennen, S Chen and J T Isaacs 2013, unpublished observations), while those isolated from cancerous prostates in older men retain their tri-lineage differentiation potential (Brennen *et al.* 2013), which may reflect their more recent exodus from the bone marrow and represent a more naïve commitment status.

Importantly, inter-individual variation in the proliferative capacity and differentiation potential of donor-derived MSCs can make the interpretation of such comparisons difficult, which can be further compounded

by differences in optimal culture conditions that are yet to be fully standardized for MSCs obtained from alternative tissue sources (Huang *et al.* 2005, Sakaguchi *et al.* 2005, Wagner *et al.* 2005, Ho *et al.* 2008, Pevsner-Fischer *et al.* 2011, Rada *et al.* 2011, Brennen *et al.* 2013). This variability can be alleviated, in part, by comparing a panel of tissue-specific MSCs isolated from a single individual. Indeed, such studies appear to confirm observations suggesting a restricted differentiation potential related to a tissue-of-origin 'memory' (Sakaguchi *et al.* 2005, Afizah *et al.* 2007). For instance, BM-MSCs have greater chondrogenic potential than ADSCs isolated from the same patient (Huang *et al.* 2005, Afizah *et al.* 2007). Sakaguchi *et al.* (2005) also demonstrated distinct differences in the differentiation efficiencies of patient-matched MSCs isolated from multiple tissues and expanded under similar conditions. Furthermore, gene expression and proteomic analyses of MSCs from different sources have also demonstrated distinct profiles despite significant similarities (Wagner *et al.* 2005, Noel *et al.* 2008, Jansen *et al.* 2010). For example, increased expression of osteogenesis- and angiogenesis-associated genes was measured in BM-MSCs and umbilical cord MSCs relative to each other respectively (Panepucci *et al.* 2004). Minimally, these observations highlight the heterogeneity of isolated MSC populations with regard to their differentiation potential, embryonic lineage, tissue source, and donor age.

MSCs in the clinic

Numerous clinical trials over the last decade were designed to exploit the multipotent differentiation potential of MSCs for a range of pathological conditions, including myocardial infarction (MI), spinal cord injury, and osteogenesis imperfecta. While promising results were obtained in early phase clinical trials, the high hopes for these MSC-based regenerative strategies were largely unrealized in the accompanying phase III trials. Follow-up on these studies suggested a lack of long-term tissue engraftment (<1%) with no evidence of differentiation into the anticipated cell types following systemic administration (Ankrum & Karp 2010). In contrast to the results from *in vitro* differentiation assays, these clinical observations questioned the assumption that MSC's primary role in tissue repair is to reconstitute damaged cell types. However, despite the lack of differentiation, there were positive therapeutic effects observed in select patients from these trials. Concurrent laboratory investigations led to an emerging realization that MSCs function through trophic and immunomodulatory mechanisms based on the secretion of bioactive molecules

(Krampera *et al.* 2003, Le Blanc *et al.* 2003b, Aggarwal & Pittenger 2005, Zimmet & Hare 2005, Iso *et al.* 2007, Prockop 2007, Caplan 2009). MSCs have been shown to secrete numerous growth factors, cytokines, and chemokines, in addition to pro-angiogenic, anti-apoptotic, and anti-inflammatory signals, including transforming growth factor β (TGF- β), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 6 (IL6), regulated on activation, normal T cell expressed and secreted (RANTES), CCL2, vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), prostaglandins (PGs), and IL10, to name a few (Newman *et al.* 2009, Zhukareva *et al.* 2010, English & Mahon 2011). Although some groups only detect IL10 in MSC-leukocyte co-cultures (Tse *et al.* 2003, Beyth *et al.* 2005, Rasmusson *et al.* 2005), others have reported the constitutive expression of IL10 by MSCs in monoculture as well (Aggarwal & Pittenger 2005, Barry *et al.* 2005, Coffelt *et al.* 2009, Mougiakakos *et al.* 2011, Technau *et al.* 2011). Additionally, molecular profiling has revealed that MSCs express a large repertoire of cytokine and chemokine receptors that are believed to mediate their trafficking to inflammatory sites (Spaeth *et al.* 2008). The paracrine effects of these secreted molecules likely explain the observed clinical benefits seen thus far and have formed the underlying rationale for the majority of current MSC-based clinical trials designed to treat various inflammatory and autoimmune disorders.

To date, a number of clinical trials have been completed in which *ex vivo* expanded MSCs have been administered for applications as diverse as enhancing cardiac function post-MI, promoting hematopoietic stem cell engraftment, mitigating graft-vs-host-disease (GVHD), and treating a host of autoimmune disorders (Lazarus *et al.* 2005, Le Blanc *et al.* 2008, Hare *et al.* 2009, Garcia-Gomez *et al.* 2010). The most commonly studied application of systemic allogeneic MSCs has been as a means to decrease or prevent GVHD. Two phase III trials enrolling a total of 452 patients have evaluated the efficacy of allogeneic MSCs in patients with GVHD have been completed. While neither trial met its primary endpoint of complete response, there were some clinical benefits observed in those with steroid-refractory GVHD. These results ultimately lead to the approval in Canada of Prochymal, a pre-manufactured, universal donor MSC product, in acute pediatric GVHD (Prasad *et al.* 2011, Osiris Therapeutics 2012). More importantly, as was true with earlier phase studies, no adverse events were noted after infusion of MSCs in any patient being treated on either GVHD protocol. A variety of phase I/II studies testing the effect of MSCs in the setting of MI, chronic obstructive pulmonary disease, liver cirrhosis, lupus, and type II

diabetes have also been reported (Hare *et al.* 2009, Jiang *et al.* 2011, Zhang *et al.* 2012, Li *et al.* 2013, Weiss *et al.* 2013). Thus far, no significant MSC-related adverse events have been reported across these various phase I/II studies (Lalu *et al.* 2012). Currently, a number of additional randomized trials are underway utilizing MSCs in a range of different diseases (Garcia-Gomez *et al.* 2010). In summary, the combined results from a large number of trials indicate that i.v. administration of unmodified human BM-MSCs, whether autologous or allogeneic, can be safely administered to patients without producing significant side effects.

MSCs: firemen of the immune system

MSCs are generally thought to be non-immunogenic due to their lack of both MHC-II expression and the associated co-stimulatory molecules (Tse *et al.* 2003). Importantly, MSCs do express low levels of MHC-I, which prevents them from being recognized and lysed by NK cells (Newman *et al.* 2009). Furthermore, the constitutive expression of factor H makes MSCs resistant to complement-mediated lysis (Tu *et al.* 2010). Secretion of factor H extends this protection to other cells in the local microenvironment and represents one of many mechanisms through which MSCs suppress both the innate and adaptive immune responses (Fig. 2). MSCs inhibit the proliferation and activation of NK cells through expression of PGs and indoleamine dioxygenase (IDO; English & Mahon 2011). MSCs secrete PGs have also been shown to suppress mast cell degranulation, trafficking, and tumor necrosis factor α (TNF α) expression (Brown *et al.* 2011), in addition to promoting macrophage M2 polarization (Prockop 2013). Secretion of TSG-6 by MSCs has multiple anti-inflammatory properties, including inhibition of TLR2-induced NF- κ B signaling in macrophages by blocking CD44 stimulation, abrogation of neutrophil migration, and suppression of pro-inflammatory protease activity (Lee *et al.* 2009, Prockop & Oh 2012, Prockop 2013). Additionally, MSCs block the secretion of pro-inflammatory cytokines from activated macrophages, prevent the oxidative burst associated with neutrophil function, and suppress eosinophil trafficking to inflammatory tissues (Newman *et al.* 2009, English & Mahon 2011). MSC-derived IL6 inhibits dendritic cell (DC) maturation from monocytes, in addition to suppressing the expression of MHC-II and the CD40 and CD86 co-stimulatory molecules required for T-cell activation (Djouad *et al.* 2007). By blocking DC maturation and antigen presentation, MSCs induce a tolerogenic phenotype in which DCs downregulate the expression of

The Innate Immune System

Figure 2

Immunosuppressive properties of MSCs on both the innate and adaptive arms of the immune system. MSC trafficking from the bone marrow in response to an inflammatory stimulus, in addition to MSCs, already present in the local microenvironment can profoundly affect the overall immune response. The immunosuppressive effects of MSCs are mediated through both direct cell contact in some cases, and the secretion of numerous paracrine signals that effect proliferation, survival, trafficking, maturation,

polarization, activation, cytotoxicity, and the secretion of additional inflammatory mediators. These effects occur between MSCs and nearly all components of both the innate and adaptive immune system, which suggests that MSCs may represent a central hub in the regulatory networks of the immune system. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-13-0151>.

pro-inflammatory cytokines, such as TNF α , while upregulating the expression of IL10 and other anti-inflammatory cytokines (Aggarwal & Pittenger 2005).

Inhibition of MHC-II-mediated antigen presentation by DCs prevents T-cell activation and proliferation. Furthermore, MSCs promote the generation of regulatory T cells; suppress Th1, Th2, and Th17 polarization; and inhibit the proliferation and activation of cytotoxic T cells (CTLs); thereby, shifting the T-cell response to an immunosuppressive state (Newman *et al.* 2009, English & Mahon 2011). Multiple studies have also demonstrated that MSCs inhibit B-cell activation, proliferation, migration, and immunoglobulin expression (Corcione *et al.* 2006, Newman *et al.* 2009). These effects are mediated by both soluble factors and direct cell–cell contact; the latter of which activates programmed death pathway-1 (PD-1) signaling and is at least partially responsible for the attenuation of B-cell proliferation and altered cytokine receptor expression in mice (Augello *et al.* 2005). These observations suggest that a primary physiological function of MSCs is to promote an immunosuppressive micro-environment (Fig. 2). This MSC-mediated immunosuppression likely represents a critical negative feedback mechanism to prevent unchecked chronic inflammation. Together with other regulatory mechanisms, this negative feedback helps to prevent an uncontrolled self-reinforcing ‘cytokine storm’, or hypercytokinemia, that can lead to increased vascular permeability, tissue edema, auto-immune disorders, fibrosis, acute respiratory distress syndrome, organ failure, cancer, or even death in extreme cases (Osterholm 2005, La Gruta *et al.* 2007).

MSCs: immunoprivileged or not?

While MSCs are traditionally thought to be non-immunogenic and immunosuppressive due to the properties described above, some recent studies have suggested that MSCs may be immunogenic under certain conditions (Eliopoulos *et al.* 2005, Nauta *et al.* 2006, Huang *et al.* 2010). The rejection of allogeneic MSCs in immunocompetent MHC mismatched mice was associated with an increase in infiltrating CTLs, natural killer T cells, and NK cells (Huang *et al.* 2010). Additionally, while syngeneic murine MSCs were associated with tolerance to both donor and recipient antigens in an allogeneic bone marrow transplant model, the same study also demonstrated that transplantation of MHC-matched MSCs and BM into an allogeneic recipient decreased engraftment efficiency (Nauta *et al.* 2006). In contrast, no effect on BM engraftment was

observed when MSCs from a third-party donor were used. Furthermore, while allogeneic MSCs only triggered rejection when they were MHC-matched to the BM donor, both third-party and BM-matched MSCs were able to induce a memory T-cell response, which strongly suggests that allogeneic murine MSCs are immunogenic (Nauta *et al.* 2006). Unlike human MSCs, which only express MHC-II following stimulation with interferon (IFN)- γ , the murine MSCs used in these studies express low levels of MHC-II under non-stimulated conditions (Eliopoulos *et al.* 2005). Unsurprisingly, this basal expression of MHC-II renders murine MSCs immunogenic in an allogeneic setting and likely explains the results observed in these studies.

Like humans and other higher order mammals, rat MSCs, in contrast to their murine cousins, do not express MHC-II antigens under basal conditions (Newman *et al.* 2009); however, induction of MHC-II expression was detected following myogenic, endothelial, and smooth muscle differentiation (Huang *et al.* 2010). Furthermore, these differentiated MSCs were cleared from recipient tissues and donor-specific alloantibodies were detected in the serum of recipient rats at 5 weeks post-injection. Similarly, expression of HLA-DR, a MHC-II antigen, is induced following chondrogenic differentiation of adipose-derived human MSCs (ADSCs) *in vitro* (Technau *et al.* 2011). Interestingly, these chondrocyte-differentiated ADSCs continued to express the immunosuppressive HLA-G antigen and secrete IL10, suggesting that they may retain their immunosuppressive properties post-differentiation. Increased immunogenicity following differentiation would potentially explain the lack of data demonstrating long-term engraftment in patients following allogeneic MSC infusion. Indeed, Niemeyer *et al.* (2008) found no evidence of BM-MSCs that were osteogenically induced *ex vivo* prior to infusion in recipient animals; by contrast, undifferentiated BM-MSCs were detected in all recipients following xenotransplantation. Additionally, both allogeneic and autologous BM-MSCs are susceptible to complement-mediated lysis in the presence of serum following *ex vivo* culturing, despite the expression of factor H and other negative regulators (Li & Lin 2012).

Other studies have demonstrated that neither differentiated nor undifferentiated allogeneic MSCs induce a proliferative response in mixed lymphocyte cultures (Le Blanc *et al.* 2003a) or in a rabbit model of osteogenesis (Liu *et al.* 2006). Additionally, early studies failed to detect alloantibodies against MSCs in the serum of patients receiving therapeutic doses of allogeneic MSCs (Le Blanc

et al. 2004, Sundin *et al.* 2007), suggesting that the immunoprivileged phenotype of MSCs remains dominant even if they do undergo differentiation *in vivo*. However, recent studies have reported the presence of anti-donor antibodies in the serum of a minority of patients. Weak alloimmune reactions were detected in 3.7% of patients in the POSEIDON randomized trial comparing allogeneic to autologous BM-MSC therapy for ischemic cardiomyopathy (Hare *et al.* 2012). In a press release reporting the results from Mesoblast's phase 2 trial evaluating MSCs in patients with cardiovascular disease, anti-donor antibodies were detected in 13% of patients (PRNewswire 2011). Importantly, no adverse clinical effects were associated with the presence of alloantibodies in either of these studies.

Ex vivo culturing conditions, particularly with respect to FBS, have been shown to affect the immunogenicity of MSCs and may explain some of the mixed results observed between laboratories (Sundin *et al.* 2007, Newman *et al.* 2009). Multiple trials evaluating the use of autologous MSCs for a variety of conditions have recently been completed or are in progress, and reports on their engraftment efficiency compared with their allogeneic counterparts will address this possibility in a more definitive manner. Importantly, there have been no adverse clinical events, immunological or otherwise, associated with either systemic or local administration of MSCs in the thousands of patients that have been accrued in these trials (Ankrum & Karp 2010, Lalu *et al.* 2012), which emphasizes the overall safety of MSC-based therapeutic strategies. The spontaneous malignant transformation of human MSCs during prolonged expansion *ex vivo* has also been raised as a potential safety concern regarding their clinical use; however, reports on this phenomenon were later corrected or retracted by admissions of contamination in the MSC cultures with other cancer cell lines (Garcia *et al.* 2010, Torsvik *et al.* 2010, Vogel 2010, Klopp *et al.* 2011). Of note, patients enrolled in MSC-based clinical trials often receive multiple doses of $>10^8$ cells, and no transformation of MSCs in these patients have been reported to date. A recent autopsy study of 18 patients receiving infusions of HLA-mismatched MSCs found no evidence of ectopic tissue formation or malignant tumors derived from donor MSCs (von Bahr *et al.* 2012). Furthermore, in eight patients with tissue samples collected more than 50 days post-infusion, low levels of MSC donor DNA ($<1/1000$) were only detected in the lung and kidney of a single patient each. These data corroborate previous clinical observations, suggesting that MSCs have limited long-term

engraftment capabilities, which serves to highlight the overall lack of tumorigenic potential for these cells in an allogeneic therapeutic setting.

MSCs: complexities and immunostimulatory properties

There is accumulating evidence to suggest that the interactions between MSCs and immunological effector cells are more complex than those previously appreciated (Fig. 3). For example, MSCs are known to inhibit the IL2-stimulated proliferation of resting NK cells; however, activated NK cells are not only more resistant to MSC-mediated proliferative suppression but have also been shown to lyse both autologous and allogeneic MSCs in the absence of IFN- γ (Spaggiari *et al.* 2006). This lysis occurs as a result of the expression of NK-activating ligands by MSCs (Spaggiari *et al.* 2006). Binding of these ligands to their cognate receptors on the surface of NK cells triggers their recognition and destruction by NK cells, despite the low levels of MHC-I expression on MSCs. Exposure to IFN- γ in an inflammatory microenvironment significantly upregulates MHC-I expression on MSCs and protects them from NK-mediated lysis (Eliopoulos *et al.* 2005, Spaggiari *et al.* 2006). Additionally, IFN- γ -stimulated MSCs also express MHC-II and can function as antigen-presenting cells (APCs; Chan *et al.* 2006, Stagg *et al.* 2006). Interestingly, these antigen-presenting properties are biphasic and only present during a narrow range of IFN- γ concentrations with high levels leading to a decrease in APC functions (Chan *et al.* 2006). MSCs also possess direct antimicrobial activity mediated through the secretion of cathelicidin hCAP-18/LL-37, a peptide with activity against both Gram-positive and -negative bacteria (Krasnodembskaya *et al.* 2010).

The differential activation of TLR signaling in MSCs has also been shown to be a critical mediator of their immunomodulatory properties (Pevsner-Fischer *et al.* 2007, Liotta *et al.* 2008). TLR-2 stimulation suppresses MSC differentiation, while promoting their proliferation and immunosuppressive phenotype (Pevsner-Fischer *et al.* 2007). By contrast, TLR-3 and -4 signaling inhibits this immunosuppressive activity without affecting their differentiation potential (Liotta *et al.* 2008). Activation of different TLR signaling pathways in response to various pathogen-associated molecular patterns (PAMPs) has also been proposed to explain the ability of MSCs to promote tissue repair and control the inflammatory reaction without negatively impacting the ability of the immune system to fight off invading pathogens (English & Mahon

2011). These observations suggest a model where MSCs would function in a dichotomous manner depending on the nature of the infectious insult and the extent of the immunological response. MSCs would initially behave as APCs to activate an adaptive response following PAMP recognition and IFN- γ stimulation, and the immunosuppressive effects would take dominance during prolonged inflammation with increasing IFN- γ levels (Fig. 3). In further support of this model, the effect of MSCs on lymphocyte proliferation seems to be dependent on the MSC-to-lymphocyte ratio present. Low ratios of MSCs to lymphocytes, as would be seen in the initial phases of inflammation, stimulated lymphocyte proliferation through soluble paracrine mediators, whereas, higher ratios, which may occur after a prolonged inflammatory response, resulted in inhibition of lymphocyte proliferation (Bocelli-Tyndall *et al.* 2009). Evolutionarily, this negative feedback mechanism would serve to limit the immune response and prevent an unbridled leukocytic infiltrate from initiating a self-reinforcing loop of chronic inflammation, which could potentially lead to associated pathological conditions. This parallels a recent model proposed by English & Mahon (2011) in which they describe MSCs as a sort of inflammatory rheostat or 'licensing switch' to modulate the immune response. Additional support for the role of IFN- γ in regulating the immunomodulatory properties of MSCs comes from observations demonstrating that MSC-mediated suppression of T-cell proliferation is enhanced by IFN- γ secreted by activated NK and T cells (Krampera *et al.* 2006, English *et al.* 2007). Furthermore, in contrast to wild-type MSCs, IFN- γ receptor 1-null MSCs were unable to prevent GVHD in mice, suggesting that inflammation and IFN- γ signaling in particular are required for the immunosuppressive effects of MSCs (Ren *et al.* 2008b). Importantly, these immunomodulatory properties are probably not dictated by IFN- γ alone but are the result of a complex interplay between IFN- γ , TNF α , and the entire panoply of inflammatory cytokines, chemokines, and signaling molecules present within the local microenvironment.

MSCs and the inflammatory prostate

A model in which MSCs play a primary role in modulating the immune response implies that these cells are present in, or continuously fluxing through, all tissues. Accumulating evidence supports this model. In addition to the bone marrow, MSCs have been isolated from a growing list of tissues, including adipose tissue, skin, muscle, dental pulp, pancreas, intestine, lung, and peripheral blood (Zuk *et al.*

2002, Kassis *et al.* 2006, Zhang *et al.* 2006, Davani *et al.* 2007, Lama *et al.* 2007, Crisan *et al.* 2008, Lanzoni *et al.* 2009, Blasi *et al.* 2011), with all available evidence suggesting that they reside in perivascular niches within all tissues (da Silva Meirelles *et al.* 2006, Crisan *et al.* 2008). While this is a rare, but detectable, population of cells within these tissues under homeostatic conditions, there is a dramatic influx from the bone marrow in response to an inflammatory insult (Spaeth *et al.* 2008, Newman *et al.* 2009). It is well known that the prostate is bombarded with inflammatory and infectious agents throughout an individual's lifetime, with as many as 80% of men showing evidence of a leukocytic infiltrate in their prostate when biopsied (De Marzo *et al.* 2007, Nickel *et al.* 2008, Sfanos & De Marzo 2012). Additionally, the formation of corpora amylacea, which are aggregates of inflammatory proteins, is thought to begin early in life and increase with age, becoming highly prevalent within the prostates of older men (Sfanos & De Marzo 2012). The presence of prostatic inflammation, or prostatitis, likely extends to all men at some point in their lives as many inflammatory stimuli will be resolved without generating overt clinical symptoms.

Therefore, it is unsurprising that MSCs can also be isolated from the prostates of both young and old men (Brennen *et al.* 2013, S Chen, W N Brennen and J T Isaacs 2013, unpublished observations). Lin *et al.* (2007) isolated cells consistent with an MSC phenotype from BPH tissue, a disease characterized by a hyper-proliferative stroma. Despite their ability to differentiate into the myogenic, adipogenic, and osteogenic lineages, the authors concluded that these cells did not represent MSCs due to their inability to generate neural cells, a property later shown to decrease with age (Hermann *et al.* 2010, Brohlin *et al.* 2012), thereby explaining the lack of this particular differentiation potential in BPH cells isolated from older men. Additionally, MSCs incorporate into the re-growing prostates of castrated mice following testosterone supplementation (Placencio *et al.* 2010). In addition to older men with prostate cancer, our own laboratory has cultivated MSCs (CD90+/FAP+/CD105+/CD73+/HLA-DR-) from the prostate of a 20-year-old healthy organ donor (S Chen, W N Brennen and J T Isaacs 2013, unpublished observations), suggesting that MSCs are present in the prostate throughout an individual's lifetime to varying degrees.

Chronic inflammation is thought to be an initiating event for prostatic carcinogenesis (Nelson *et al.* 2003, De Marzo *et al.* 2007). Numerous factors have been implicated in the initiation of an inflammatory microenvironment within the prostate, including diet, infectious agents, physical trauma induced by corpora amylacea, hormonal

Figure 3

The dichotomous role of MSCs in modulating the immune response depends on the degree of the immunological assault. Evidence suggests that during the initial stages of an inflammatory response, MSCs can behave as antigen-presenting cells and have immunostimulatory effects that activate an adaptive immune response following PAMP recognition and IFN- γ stimulation. As concentrations of IFN- γ , TNF α , and other inflammatory cytokines rise during prolonged inflammation and the lymphocyte-to-MSC ratio increases, the immunosuppressive properties gain dominance and serve as a negative feedback mechanism to prevent unchecked chronic inflammation that can contribute to pathogenesis. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-13-0151>.

changes, and urine reflux (Sfanos & De Marzo 2012). Independent of the cause, the resulting inflammatory signals act as a chemoattractant for circulating BM-MSCs (Fig. 1) due to the extensive array of chemokine and cytokine receptors expressed on their cell surface (Spaeth *et al.* 2008). CXCL12 (SDF-1), CCL5 (RANTES), and CCL2 (MCP-1), in particular, have been shown to be highly overexpressed in prostate cancer (Sun *et al.* 2003, Vaday *et al.* 2006, Fujita *et al.* 2010), all of which have also been implicated in MSC trafficking to inflammatory sites (Spaeth *et al.* 2008). Multipotent MSCs of mouse origin have been isolated from prostate cancer xenografts using a side population assay (Santamaria-Martinez *et al.* 2009). Additional evidence consistent with the presence of MSCs in human prostate cancer includes the characteristic overexpression of CD90 (True *et al.* 2010), a marker of not only MSCs but also endothelial cells, hematopoietic precursors, neurons, thymocytes, and NK cells. Interestingly, in a series of prostate cancer tissue samples with high CD90 expression, these same authors showed a non-comparable increase in CD45-positive cells, suggesting that the increased CD90 expression was not merely due to excessive leukocyte infiltration (Liu *et al.* 2004). Importantly, not all these extra CD90-positive cells are likely to represent bona fide MSCs as this population also includes MSCs at various stages of differentiation, endothelial cells, hematopoietic progenitors, and carcinoma-associated fibroblasts (CAF). Furthermore, while CD90 expression is significantly elevated in malignant prostatic lesions, rare CD90+ cells

can also be detected in normal prostate tissue (Zhao & Peehl 2009, True *et al.* 2010), which is consistent with the presence of a small population of MSCs in all tissues. CD90-positive cells have also been identified in cultures isolated from primary human prostatic stromal cells (Zhao & Peehl 2009). While the authors of this study concluded that these cells did not represent MSCs, it should be noted that CD90hi cells were only compared with CD90lo, rather than CD90-negative cells. Additionally, the differentiation potential of these two CD90-positive populations was not investigated. We would suggest that both these populations likely represent MSCs, albeit potentially ones at different stages of differentiation or lineage commitment. Our own studies clearly indicate the presence of MSCs in multiple primary prostate cancer specimens obtained directly from the operating room prior to expansion in tissue culture (Brennen *et al.* 2013). While CD90 expression has been proposed as a potential cancer biomarker (True *et al.* 2010), the relationship between CD90 expression and PIA or PIN, which are believed to be prostate cancer precursor lesions, has not been studied. Coupled with other characteristic MSC markers, this would help to determine whether MSCs traffic to these inflammatory precursor lesions as an early event in prostate carcinogenesis.

MSCs: effects on tumor progression and metastasis

The role of MSCs in the pathogenesis of cancer is complex and likely related to the balance of competing pro- and anti-tumorigenic forces. Numerous mechanisms have been proposed to play a role in the ability of MSCs to promote tumor growth, including stimulation of proliferation, angiogenesis, and metastasis, in addition to the immunosuppressive properties described earlier. Co-inoculation of MSCs with tumor cells has been shown to increase xenograft growth in models of melanoma and lymphoma, in addition to colon, breast, and lung cancer (Bergfeld & DeClerck 2010, Klopp *et al.* 2011). Tumor growth can be further fueled by promoting an increased tumor vasculature through the secretion of pro-angiogenic factors by MSCs, including VEGF, TGF- β , platelet-derived growth factor (PDGF), and basic fibroblast growth factor (bFGF) (Bergfeld & DeClerck 2010, Bianchi *et al.* 2011). MSCs are also frequently found in perivascular niches and can promote vessel stabilization through pericyte-like functions (da Silva Meirelles *et al.* 2006, Crisan *et al.* 2008, Bianchi *et al.* 2011). Additionally, MSCs have been shown to enhance the metastatic potential of breast and colon cancer cells in xenograft models

(Karnoub *et al.* 2007, Klopp *et al.* 2011), in addition to promoting a pro-tumorigenic environment in the bone marrow (Bergfeld & DeClerck 2010). The immunosuppressive properties of MSCs have also been proposed as a mechanism to enable the tumor to escape host immune surveillance (Bergfeld & DeClerck 2010). Extensive reviews on the relationship between MSCs and cancer have previously been published elsewhere (Bergfeld & DeClerck 2010, Bianchi *et al.* 2011, Klopp *et al.* 2011).

While the pro-tumorigenic role of MSCs is more easily understood, there are also a large number of studies demonstrating anti-tumorigenic effects of MSCs for reasons that are less clear (Klopp *et al.* 2011) but include pro-inflammatory effects and the downregulation of survival signals mediated through the Akt and Wnt pathways (Ohlsson *et al.* 2003, Khakoo *et al.* 2006, Qiao *et al.* 2008). An attempt to reconcile these conflicting observations has recently been discussed by Marini and colleagues, who conclude that there is currently no clear explanation for these divergent findings (Klopp *et al.* 2011). The dichotomous role of MSCs in the immune system likely plays a role in this tumorigenic response; however, both pro- and anti-tumorigenic effects have been observed in both immunocompromised and immunocompetent animals, suggesting that this relationship is more complex than merely a function of their immunomodulatory properties.

MSCs: role in prostate carcinogenesis

Specifically, with regard to MSCs and prostate cancer, several *in vitro* investigations have attempted to understand how the interactions between these two cell types may contribute to carcinogenesis in both the primary and the metastatic tumor microenvironments (Fig. 1). FGF-9 and paracrine factors secreted by bone metastatic PC3 cells stimulate osteoblastic differentiation of human BM-MSCs, whereas conditioned medium from non-metastatic CWR22Rv1 cells did not (Fritz *et al.* 2011). This is particularly interesting in light of the well-known observation that prostate cancer frequently generates osteoblastic lesions when it metastasizes to the bone. Later studies demonstrated that the pro-osteoblastic effect of PC3-conditioned media (PC3-CM) was due to the presence of epidermal growth factor receptor (EGFR) ligands, which also stimulated the proliferation of human BM-MSCs, but suppressed adipocyte and osteoclast differentiation (Borghese *et al.* 2012). Interestingly, significant levels of new bone formation *in vivo* were only observed when MSCs were injected intra-tibially in the presence of PC3 cancer cells but not in their absence (Chanda *et al.*

2009). PC3-CM also stimulated IL6 and CCL5 secretion by MSCs, the latter of which led to increased cell migration; reciprocally, MSCs not only promoted PC3 proliferation and colony formation but also protected them from docetaxel-induced toxicity through paracrine mediators (Borghese *et al.* 2012). Of note, in response to radiation and cytotoxic chemotherapies, stromal cells in the prostate tumor microenvironment were recently shown to secrete paracrine factors, including WNT16B, that promote the survival of adjacent cancer cells and lead to enhanced therapeutic resistance (Sun *et al.* 2012). Ye *et al.* (2012) have shown that media conditioned by human BM-MSCs not only upregulates MMP-2/-9 expression in PC3 cells but also promotes their migration and invasion via TGF- β signaling pathways. Additionally, oncostatin M was recently shown to induce both TGF- β 1 and periostin expression in human ADSCs and promote PC3 adhesion (Lee *et al.* 2013).

To date, there have only been a limited number of studies investigating the effect of MSCs on prostate tumor growth *in vivo*, and the majority of those have demonstrated little to no effect (Table 1). It should be mentioned, however, that most of these studies have utilized the PC3 cell line, and therefore, these analyses should be extended into other models before making generalized conclusions. Khakoo *et al.* (2006) demonstrated that human BM-MSCs suppress tumor growth in a model of Kaposi's sarcoma by inhibiting Akt activation in a cell contact-dependent manner; however, when co-cultured with PC3 cells, these same MSCs had no effect on phospho-Akt levels, nor did they alter xenograft growth in immunocompromised animals. No effect on tumor weight or animal survival was observed in mice bearing PC3 tumors who received three weekly i.v. injections of 2×10^6 human BM-MSCs (Wang *et al.* 2012). Rat BM-MSCs transduced with the herpes simplex virus thymidine kinase gene (HSV-TK) had no effect on PC3 xenograft growth in the absence of ganciclovir treatment (Song *et al.* 2011). Additionally, human BM-MSCs had no effect on tumor take or growth rates when co-injected with DU145 cells (Pessina *et al.* 2011). A study by Zhang *et al.* (2011) demonstrated that rat BM-MSCs injected into already established tumors had no effect on PC3 xenograft growth. Additionally, C3H10T1/2 embryonic murine MSCs co-injected with PC3 cells also had no effect on intratibial tumor growth (Fritz *et al.* 2008). By contrast, Chanda *et al.* (2009) showed that adult murine MSCs injected into already established intratibial PC3 tumors suppressed their growth and promoted bone regeneration, although the effect was less pronounced than when the MSCs were co-injected with the tumor cells simultaneously. Using the

Table 1 Effects of MSCs on prostate cancer growth in preclinical animal models

Effect on tumor growth	Species (MSC)	Tissue source	Mouse strain	Tumor model	Immunogenicity	MSC:cancer cell ratio (no. of MSCs)	Delivery route	Timing (post-inoculation)	MSC injections (#)	Results	Proposed mechanism	Reference
–	Human	Bone marrow	SCID	PC3	Allogeneic	1:6.7 (3×10^5)	MSC: i.v.; tumor: s.c.	d14, 21, 28+ (35 and 42)	Growth: 3; survival: 5	No effect on tumor growth or survival		Wang et al. (2012)
–	Human	Bone marrow	Nude	PC3	Allogeneic	1:1.25 (4×10^6)	MSC: i.v.; tumor: s.c.	d0, 3, and 10	3	No effect on tumor growth		Khakoo et al. (2006)
–	Human	Bone marrow	NOD/SCID	DU145	Allogeneic	1:5 (0.4×10^6)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	No effect on tumor take or growth		Pessina et al. (2011)
–	Human	Adipose	Nude	PC3	Allogeneic	1:5 (2×10^5)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	No effect on tumor growth		Zolochovska et al. (2012)
–	Human	Adipose	Nude	PC3-M	Allogeneic	1:1 (1×10^6)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	No effect on tumor growth		Lee et al. (2013)
↓/↑	Human	Adipose	Nude	PC3	Allogeneic	s.c.: 2:5 ($1.2-1.6 \times 10^6$) i.v.: 1:1.5 or 1:1 ($2-3 \times 10^6$)	MSC: s.c. or i.v. tumor: s.c.	s.c.: d0 (co-inoculation) i.v.: d7 and d18	s.c.: 1 i.v.: 1 or 2	s.c.: increased tumor growth and mortality by a couple of days i.v.: suppressed tumor growth	None proposed	Cavarretta et al. (2010)
↑	Human	Adipose	Nude	PC3	Allogeneic	1:2 (1×10^6)	MSC: s.c. (left flank); tumor: s.c. (right flank)	d7	1	Increased tumor growth	CXCL12/CXCR4 axis; increased capillary density; FGF2 expression	Lin et al. (2010)
↑	Human	Adipose	Nude	MDA-PCa-118b	Allogeneic	1:10 (1×10^5)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	Increased tumor growth	None proposed	Prantl et al. (2010)
↑	Human	Bone marrow	Nude	PC3	Allogeneic	1:5 (1×10^6)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	Increased tumor growth	TGF- β signaling	Ye et al. (2012)
↑	Human	Bone marrow	SCID	PC3	Allogeneic	1:100 (2×10^3)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	Increased tumor growth	CXCL16/CXCR6	Jung et al. (2013)
↓	Mouse	Bone marrow	SCID	PC3	Allogeneic	5:1 (5×10^5)	MSC: i.v.; tumor: s.c.	d1 or d14	1	Suppressed tumor growth effect less pronounced in established tumors; promoted bone regeneration in the presence of cancer cells	New bone formation restricted growth of cancer cells	Chanda et al. (2009)
–	Mouse	Bone marrow	SCID	PC3	Allogeneic	1:1 and 3:1 (0.5 and 1.5×10^6)	MSC: i.v.; tumor: i.v.	d0 (co-inoculation)	1	No effect on tumor growth at either ratio		Fritz et al. (2008)
–	Mouse	Bone marrow	C57BL/6	TRAMP-C2	Syngeneic	1:2.5 (2×10^5)	MSC: i.v.; tumor: i.v.	d10	1	No effect on lung metastasis		Ren et al. (2008a,b)
–	Mouse	Adipose	C57BL/6	TRAMP-C2-Ras	Syngeneic	1:5 (4×10^5)	MSC: s.c.; tumor: s.c.	d0 (co-inoculation)	1	No effect on tumor growth		Zolochovska et al. (2012)
–	Rat	Bone marrow	Nude	PC3	Allogeneic	1:20 (1×10^6)	MSC: i.v.; tumor: s.c.	d3 and 10	2	No effect on tumor growth		Song et al. (2011)
–	Rat	Bone marrow	Nude	PC3	Allogeneic	1:1 (2×10^6)	MSC: i.v.; tumor: s.c.	d14, 21, and 28	3	No effect on tumor growth		Zhang et al. (2011)

TRAMP-C2 model, Ren *et al.* (2008a) demonstrated that murine BM-MSCs had no effect on lung metastasis when injected 10 days post-tumor cell inoculation. Zolochovska *et al.* (2012) showed that human ADSCs had no effect on PC3 xenograft growth in immunocompromised animals nor did murine ADSC significantly stimulate xenograft growth in the immunocompetent TRAMP-C2-*Ras* model. Lee *et al.* (2013) also demonstrated that co-inoculation of human ADSC had no effect on PC3-M xenograft growth in the absence of oncostatin M.

By contrast, Lin *et al.* (2010) showed that implanted ADSCs were recruited to PC3 xenografts on the opposite flank via the CXCL12/CXCR4 axis where they stimulated tumor growth, at least partially through enhanced angiogenesis and FGF2 expression. A study by Cavarretta *et al.* (2010) also suggested that unmodified human ADSCs co-injected subcutaneously with PC3 cells accelerated tumor growth and mortality by a few days; however, systemically administered ADSCs expressing cytosine deaminase (CD) significantly suppressed PC3 tumor growth even in the absence of 5-fluorocytosine (5-FC) treatment. Additionally, Prantl *et al.* (2010) reported increased tumor growth when MDA-PCA-118b cells were co-inoculated with human ADSCs. In contrast to previous reports, Ye *et al.* (2012) observed a significant increase in tumor volumes when PC3 cells were co-injected with human BM-MSCs. Taichman and colleagues recently reported that human BM-MSC stimulated PC3 xenograft growth when co-inoculated at ratios of 1:100 through a CXCR6/CXCL16-dependent mechanism (Jung *et al.* 2013). They further demonstrated that the recruitment of murine MSC to murine RM1 prostate cancer tumors *in vivo* was CXCL16 dependent and the number of MSCs present in the tumor correlated with tumor growth. Furthermore, CXCR6 signaling in BM-MSC induced their conversion to a CXCL12-expressing CAF phenotype, which has been implicated in prostate cancer metastasis (Jung *et al.* 2013).

These conflicting results regarding the influence of MSCs on prostate cancer growth may be due to differences in the ratio of MSCs to tumor cells, the absolute number of MSCs injected, or the timing of their administration relative to tumor inoculation. Furthermore, there does not seem to be a clear relationship between the immunogenicity of the MSCs and tumor cells used nor the immunological status of the xenograft hosts (Table 1). Of note, a recent study by Marini and colleagues suggested that local ADSCs were more likely to be integrated into the fibrovascular network of the early tumor, whereas their bone marrow-derived counterparts were more likely to be localized to the tumor periphery where they may play a

role in tissue remodeling and metastasis (Kidd *et al.* 2012). Interestingly, there does seem to be a higher incidence of pro-tumorigenic effects observed in experiments using ADSCs compared with BM-MSCs in the prostate-specific studies described earlier and in those reviewed by Klopp *et al.* (2011), but this is not exclusively true.

Both ADSCs and BM-MSCs have also been shown to give rise to CAF (Fig. 1; Mishra *et al.* 2008, 2009, Paunescu *et al.* 2011, Kidd *et al.* 2012, Jung *et al.* 2013), which have been implicated in nearly all stages of prostate cancer carcinogenesis, including initiation, progression, invasion, and metastasis (Chung 1991, Olumi *et al.* 1999, Bhowmick *et al.* 2004, Franco *et al.* 2010, Giannoni *et al.* 2010, Brennen *et al.* 2012, Li *et al.* 2012). Human prostate-derived CAF co-implanted with initiated but non-tumorigenic human prostate epithelium into immunocompromised murine hosts significantly enhances tumor growth (Olumi *et al.* 1999). Loss of TGF- β responsiveness in fibroblasts through genetic manipulation results in murine PIN-like lesions (Bhowmick *et al.* 2004) and promotes mixed bone lesions in intratibial models of metastasis (Li *et al.* 2012). Conditioned media from activated fibroblasts promotes epithelial-to-mesenchymal transition in PC3 cells *in vitro*, in addition to stimulating invasiveness and prostasphere formation (Giannoni *et al.* 2010). These same authors went on to demonstrate that prostate-derived CAF enhanced PC3 aggressiveness *in vivo* by promoting tumor formation and facilitating lung micrometastases (Giannoni *et al.* 2010). The role of CAF in the progression of tumors from multiple tissues, including breast, colon, and pancreas in addition to the prostate, are well described and have been extensively reviewed elsewhere (Kalluri & Zeisberg 2006, Orimo & Weinberg 2006, Franco *et al.* 2010, Shimoda *et al.* 2010). Our own studies suggest that CAF derived from human prostates are enriched in MSCs (Brennen *et al.* 2013). These seemingly contradictory observations regarding the well-known tumor-promoting properties of CAF and the lack of any effect in the majority of the studies described earlier using MSCs serves to further reinforce the idea that MSCs isolated from different compartments have divergent phenotypes. Perhaps unsurprisingly, this implies that prostate-derived CAF are different than the BM-MSCs from which at least a subset of them is derived. These differences likely arise as a result of their developmental origin and distinct signaling events received through interactions with the tissue and tumor microenvironments in which they are found. Additionally, these CAF may pass through an ADSC intermediate stage depending on their mode of recruitment, which may further add to

the complexity and heterogeneity observed in the phenotypic and functional differences observed in these cells (Kidd *et al.* 2012).

MSCs: tumor-targeting vectors

Available evidence strongly suggests that the inherent tropism of MSCs for tumor tissue can be exploited to deliver therapeutic and diagnostic agents. Indeed, much preclinical work has already been performed in this area using MSCs derived from a variety of species and tissue sources (Ciavarella *et al.* 2011, Shah 2012). In addition to the tumor-targeting properties of MSCs, their immunoprivileged nature suggests that large quantities of these cells can be harvested from a healthy donor, expanded, and manipulated *ex vivo* prior to infusion into multiple allogeneic patients as an 'off-the-shelf' therapy. This latter point not only makes this therapeutic strategy more practical with regard to time and cost but also alleviates ethical considerations related to re-infusing the cancer patient's own (autologous) cells with regard to their potential to influence tumor malignancy.

A common theme of these strategies is to utilize genetic engineering techniques to generate MSCs that express various molecules with anticancer properties, which are then delivered to the tumor by the MSCs via systemic circulation. Generally, these MSC-delivered anticancer agents fall into one of several categories: immunostimulatory agents, oncolytic viruses, growth factor antagonists, pro-apoptotic factors, anti-angiogenic compounds, or prodrug-converting enzymes. Marini *et al.* pioneered the use of adenoviral transduced MSCs to deliver IFN- β to sites of cancer and have demonstrated efficacy in preclinical models of melanoma, breast, and pancreatic cancer (Studený *et al.* 2002, 2004, Kidd *et al.* 2010). Delivery of IFN- β by genetically engineered MSCs has also shown efficacy in models of prostate bone and lung metastasis (Ren *et al.* 2008a, Chanda *et al.* 2009). Additional immunostimulatory agents, including IL2, IL7, IL12, IL18, IL23, and CX3CL1, have also been engineered into the MSC genome and used to treat a variety of preclinical cancer models, such as glioma, melanoma, Ewing's sarcoma, and renal cell carcinoma (Nakamura *et al.* 2004, Elzaouk *et al.* 2006, Duan *et al.* 2009, Gao *et al.* 2010, Gunnarsson *et al.* 2010).

Multiple groups have also begun developing MSCs as delivery vectors for oncolytic viruses (Nakashima *et al.* 2010). Cell-based delivery of oncolytic viruses cannot only enhance the tumor-targeting potential of these viruses but can also reduce their neutralization by shielding them

from pre-existing antiviral antibodies (Mader *et al.* 2009, Huang *et al.* 2013). Dembinski *et al.* (2010) demonstrated that delivery of a conditionally replicating fiber-modified adenoviral vector using MSCs reduced off-target infection and systemic toxicity following i.p. injection in a model of disseminated ovarian cancer. The Pereboeva and Curiel groups have also shown increased efficacy and survival following therapy with conditionally replicating adenovirus-transduced MSCs in ovarian xenograft and breast cancer lung metastasis models (Komarova *et al.* 2006, Stoff-Khalili *et al.* 2007).

The delivery of various prodrug-converting enzymes, including carboxylesterases, CD, and HSV-TK, have also generated provocative results in various preclinical models. Co-inoculation of MSCs expressing HSV-TK with PC3 prostate cancer cells inhibited xenograft growth when treated with ganciclovir, but not in its absence (Song *et al.* 2011). Furthermore, systemically delivered MSCs expressing HSV-TK showed efficacy against orthotopic pancreatic and hepatic xenograft growth and reduced the incidence of pancreatic metastasis (Zischek *et al.* 2009, Niess *et al.* 2011). Altaner and colleagues demonstrated that both co-inoculated and systemically administered ADSCs engineered to express CD significantly reduced tumor burden in animals bearing PC3 prostate cancer xenografts following daily doses of 5-FC (Cavarretta *et al.* 2010). This same group has also shown efficacy against HT-29 colon cancer and A375 melanoma xenograft growth *in vivo* using CD-transduced ADSCs (Kucerova *et al.* 2007, 2008). Additionally, MSCs engineered to express carboxylesterase, which metabolizes CPT-11 into an active topoisomerase I inhibitor (SN-38), have shown efficacy against mouse models of glioma (Yin *et al.* 2011, Choi *et al.* 2012).

Additional strategies seeking to utilize the tumor-targeting properties of MSCs include the delivery of pro-apoptotic factors, such as TRAIL (Grisendi *et al.* 2010, Shah 2012); anti-angiogenic agents, such as thrombospondin-1 (van Eekelen *et al.* 2010) and endostatin (Yin *et al.* 2011); and growth factor antagonists, such as NK4 (Kanehira *et al.* 2007). An interesting approach recently described by Spitzweg *et al.* permits both imaging and therapy to be performed using MSCs transfected with the sodium iodide symporter (NIS), which is normally responsible for concentrating iodide in the thyroid (Knoop *et al.* 2011). NIS expression not only resulted in selective accumulation of iodine in hepatocellular tumors in mice, which made both ^{123}I scintigraphy and ^{124}I PET imaging possible but also abrogated xenograft growth following systemic administration of the radionuclide ^{131}I .

While these strategies have shown great promise in numerous preclinical models, none have entered into clinical trials yet, although the relatively short time frame since their inception precludes any judgment on their eventual clinical potential. In fact, the world's first unmodified MSC therapy only received approval as recently as 2012 in Canada for the treatment of GVHD (Osiris Therapeutics 2012). However, one attribute of these approaches that may ultimately harm their clinical translation is the failure to take into consideration the trafficking of MSCs to multiple sites throughout the body in addition to the tumor following systemic infusion after the initial entrapment in the lung, including the spleen, kidneys, liver, bone marrow, and other sites of inflammation and remodeling (Gao *et al.* 2001, Devine *et al.* 2003, Allers *et al.* 2004, Detante *et al.* 2009, Choi *et al.* 2011, von Bahr *et al.* 2012). This may increase the off-target/non-tumor effects and systemic toxicity associated with these therapies following infusion. One strategy to circumvent these potential off-target effects is the use of MSCs to deliver prodrugs that are activated in a tumor- or tissue-specific manner. As one example, ongoing studies in our own laboratory in collaboration with multiple other groups are seeking to develop MSCs as vectors to deliver prostate-specific antigen (PSA)-activated prodrugs (Denmeade *et al.* 2003) and protoxins (Williams *et al.* 2007) to sites of metastatic prostate cancer using multiple therapeutic platforms, including nanoparticle-loading strategies and genetic manipulation (Brennen *et al.* 2013). In this therapeutic scenario, prodrugs delivered by MSCs to nontarget tissues will not be activated due to the lack of enzymatically active PSA, which is only present in the prostate and at sites of prostate cancer metastases, thereby reducing systemic toxicity. Additionally, Karp and colleagues have demonstrated that MSC homing and engraftment in inflamed tissue can be increased by decorating their surface with proteins involved in leukocyte extravasation (Sarkar *et al.* 2011). Cell engineering strategies such as this and continued optimization of viral transduction methods for MSCs (Lin *et al.* 2012) will help translate these strategies into the clinic more efficiently.

Summary

In summary, MSCs have emerged as critical regulators of the immune response. The role of these cells in both the innate and adaptive immunity is complex and has yet to be fully elucidated. MSCs have a multitude of immunosuppressive properties through effects on nearly every component of the immune system. Additionally, MSCs

also have immunostimulatory effects on many of these same components under specific conditions, particularly during the initial phases of an immunological assault. The balance between these competing forces, which is dictated by IFN- γ and the rest of the inflammatory cytokine milieu, plays a role in numerous pathological maladies, including cancer. MSCs and their progeny have a complex role in tumor biology with both pro- and anti-tumorigenic effects being described. While the immunomodulatory properties of these cells certainly play an important role in this relationship, available evidence suggests that the whole story is far more complex and dependent on numerous interactions with other cells present in the tumor microenvironment, both static residents and dynamic infiltrators. However, despite the incomplete understanding of MSC physiology, current data strongly suggest that these cells have an inherent tropism for tumor tissue based on the inflammatory microenvironment frequently present. These tumor trafficking properties, immunoprivileged nature, and expansion capabilities have the potential for exploitation as a cell-based delivery vector for therapeutic and diagnostic purposes. Cell-based treatment modalities attempting to harness the bodies' own physiology for therapeutic benefit have gained traction over the last few years in a variety of diseases and are sure to represent a growing trend in promising anticancer strategies of the future.

Declaration of interest

S R Denmeade and J T Isaacs have licensed PRX302 to and receive royalties from Sophiris Bio, Corp. Both these relationships for S R Denmeade and J T Isaacs have been disclosed and are under the management of the Johns Hopkins University School of Medicine Conflict of Interest Committee.

Funding

S R Denmeade and J T Isaacs are consultants for GenSpera, Inc. and have received equity and financial compensation.

Acknowledgements

The authors would like to acknowledge the Department of Defense (W N Brennen, Post-Doctoral Fellowship, W81XWH-12-1-0049), the Patrick C Walsh Fund (J T Isaacs), the Maryland Stem Cell Research Fund (J T Isaacs, RFA-MD-07-01), the Prostate Cancer Foundation/Movember Challenge Award (J T Isaacs), and National Cancer Institute Comprehensive Center (P50CA058236) and SPOR (P30CA006973) grants for their financial support.

References

Afizah H, Yang Z, Hui JH, Ouyang HW & Lee EH 2007 A comparison between the chondrogenic potential of human bone marrow stem cells

- (BMSCs) and adipose-derived stem cells (ADSCs) taken from the same donors. *Tissue Engineering* **13** 659–666. (doi:10.1089/ten.2006.0118)
- Aggarwal S & Pittenger MF 2005 Human mesenchymal stem cells modulate allogeneic immune cell responses. *Blood* **105** 1815–1822. (doi:10.1182/blood-2004-04-1559)
- Allers C, Sierralta WD, Neubauer S, Rivera F, Minguell JJ & Conget PA 2004 Dynamic of distribution of human bone marrow-derived mesenchymal stem cells after transplantation into adult unconditioned mice. *Transplantation* **78** 503–508. (doi:10.1097/01.TP.0000128334.93343.B3)
- Ankrum J & Karp JM 2010 Mesenchymal stem cell therapy: two steps forward, one step back. *Trends in Molecular Medicine* **16** 203–209. (doi:10.1016/j.molmed.2010.02.005)
- Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R & Pennesi G 2005 Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. *European Journal of Immunology* **35** 1482–1490. (doi:10.1002/eji.200425405)
- von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, Uzunel M, Ringden O & Le Blanc K 2012 Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. *Stem Cells* **30** 1575–1578. (doi:10.1002/stem.1118)
- Barry FP, Murphy JM, English K & Mahon BP 2005 Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. *Stem Cells and Development* **14** 252–265. (doi:10.1089/scd.2005.14.252)
- Bergfeld SA & DeClerck YA 2010 Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. *Cancer Metastasis Reviews* **29** 249–261. (doi:10.1007/s10555-010-9222-7)
- Berry SJ, Coffey DS, Walsh PC & Ewing LL 1984 The development of human benign prostatic hyperplasia with age. *Journal of Urology* **132** 474–479. (doi:10.1242/jcs.02511)
- Bertani N, Malatesta P, Volpi G, Sonogo P & Perris R 2005 Neurogenic potential of human mesenchymal stem cells revisited: analysis by immunostaining, time-lapse video and microarray. *Journal of Cell Science* **118** 3925–3936. (doi:10.1242/jcs.02511)
- Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H, Galun E & Rachmilewitz J 2005 Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. *Blood* **105** 2214–2219. (doi:10.1182/blood-2004-07-2921)
- Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG & Moses HL 2004 TGF- β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. *Science* **303** 848–851. (doi:10.1126/science.1090922)
- Bianchi G, Borgonovo G, Pistoia V & Raffaghello L 2011 Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells. *Histology and Histopathology* **26** 941–951.
- Bianco P, Robey PG & Simmons PJ 2008 Mesenchymal stem cells: revisiting history, concepts, and assays. *Cell Stem Cell* **2** 313–319. (doi:10.1016/j.stem.2008.03.002)
- Bissell MJ & Hines WC 2011 Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression *Nature Medicine* **17** 320–329. (doi:10.1038/nm.2328)
- Blasi A, Martino C, Balducci L, Saldarelli M, Soleti A, Navone SE, Canzi L, Cristini S, Invernici G, Parati EA et al. 2011 Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. *Vascular Cell* **3** 5. (doi:10.1186/2045-824X-3-5)
- Bocelli-Tyndall C, Bracci L, Schaeren S, Feder-Mengus C, Barbero A, Tyndall A & Spagnoli GC 2009 Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the *in vitro* proliferation of lymphocytes stimulated by interleukins 2, 7 and 15. *Annals of the Rheumatic Diseases* **68** 1352–1359. (doi:10.1136/ard.2008.094003)
- Borghese C, Cattaruzza L, Pivetta E, Normanno N, De Luca A, Mazzucato M, Celegato M, Colombatti A & Aldinucci D 2012 Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity. *Journal of Cellular Biochemistry* **114** 1135–1144. (doi:10.1002/jcb.24456)
- Brennen WN, Isaacs JT & Denmeade SR 2012 Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. *Molecular Cancer Therapeutics* **11** 257–266. (doi:10.1158/1535-7163.MCT-11-0340)
- Brennen WN, Chen S, Denmeade SR & Isaacs JT 2013 Quantification of mesenchymal stem cells (MSCs) at sites of human prostate cancer. *Oncotarget* **4** 106–117.
- Brohlin M, Kingham PJ, Novikova LN, Novikov LN & Wiberg M 2012 Aging effect on neurotrophic activity of human mesenchymal stem cells. *PLoS ONE* **7** e45052. (doi:10.1371/journal.pone.0045052)
- Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD & Mezey E 2011 Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism. *Clinical and Experimental Allergy* **41** 526–534. (doi:10.1111/j.1365-2222.2010.03685.x)
- Caplan AI 1991 Mesenchymal stem cells. *Journal of Orthopaedic Research* **9** 641–650. (doi:10.1002/jor.1100090504)
- Caplan AI 2009 Why are MSCs therapeutic? New data: new insight *Journal of Pathology* **217** 318–324. (doi:10.1002/path.2469)
- Cavarretta IT, Altanerova V, Matuskova M, Kucerova L, Culig Z & Altaner C 2010 Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. *Molecular Therapy* **18** 223–231. (doi:10.1038/mt.2009.237)
- Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM & Rameshwar P 2006 Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon- γ . *Blood* **107** 4817–4824. (doi:10.1182/blood-2006-01-0057)
- Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, Siegal GP, Beatty MS & Ponnazhagan S 2009 Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. *Clinical Cancer Research* **15** 7175–7185. (doi:10.1158/1078-0432.CCR-09-1938)
- Choi KS, Ahn SY, Kim TS, Kim J, Kim BG, Han KH, Ban SJ, Kim HS, Choi Y & Lim CJ 2011 Characterization and biodistribution of human mesenchymal stem cells transduced with lentiviral-mediated BMP2. *Archives of Pharmacol Research* **34** 599–606. (doi:10.1007/s12272-011-0410-y)
- Choi SA, Lee JY, Wang KC, Phi JH, Song SH, Song J & Kim SK 2012 Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas. *European Journal of Cancer* **48** 129–137. (doi:10.1016/j.ejca.2011.04.033)
- Chung LW 1991 Fibroblasts are critical determinants in prostatic cancer growth and dissemination. *Cancer Metastasis Reviews* **10** 263–274. (doi:10.1007/BF00050797)
- Ciavarella S, Dominici M, Dammacco F & Silvestris F 2011 Mesenchymal stem cells: a new promise in anticancer therapy. *Stem Cells and Development* **20** 1–10. (doi:10.1089/scd.2010.0223)
- Clouston D & Bolton D 2012 *In situ* and intraductal epithelial proliferations of prostate: definitions and treatment implications. Part 1: prostatic intraepithelial neoplasia. *BJU International* **109** (Suppl 3) 22–26. (doi:10.1111/j.1464-410X.2012.11040.x)
- Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, Tomchuck SL, Honer zu Bentrup K, Danka ES, Henkle SL et al. 2009 The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. *PNAS* **106** 3806–3811. (doi:10.1073/pnas.0900244106)
- Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Rizzo M, Gualandi F, Mancardi GL, Pistoia V et al. 2006 Human mesenchymal stem cells modulate B-cell functions. *Blood* **107** 367–372. (doi:10.1182/blood-2005-07-2657)
- Correia AL & Bissell MJ 2012 The tumor microenvironment is a dominant force in multidrug resistance. *Drug Resistance Updates* **15** 39–49. (doi:10.1016/j.drug.2012.01.006)

- Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, Andriolo G, Sun B, Zheng B, Zhang L *et al.* 2008 A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell* **3** 301–313. (doi:10.1016/j.stem.2008.07.003)
- Cunha GR, Hayward SW, Wang YZ & Ricke WA 2003 Role of the stromal microenvironment in carcinogenesis of the prostate. *International Journal of Cancer* **107** 1–10. (doi:10.1002/ijc.11335)
- Davani B, Ikonomou L, Raaka BM, Geras-Raaka E, Morton RA, Marcus-Samuels B & Gershengorn MC 2007 Human islet-derived precursor cells are mesenchymal stromal cells that differentiate and mature to hormone-expressing cells *in vivo*. *Stem Cells* **25** 3215–3222. (doi:10.1634/stemcells.2007-0323)
- Dayyani F, Gallick GE, Logothetis CJ & Corn PG 2011 Novel therapies for metastatic castrate-resistant prostate cancer. *Journal of the National Cancer Institute* **103** 1665–1675. (doi:10.1093/jnci/djr362)
- Delongchamps NB, Singh A & Haas GP 2006 The role of prevalence in the diagnosis of prostate cancer. *Cancer Control* **13** 158–168.
- De Marzo AM, Marchi VL, Epstein JI & Nelson WG 1999 Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. *American Journal of Pathology* **155** 1985–1992. (doi:10.1016/S0002-9440(10)65517-4)
- De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB & Nelson WG 2007 Inflammation in prostate carcinogenesis. *Nature Reviews. Cancer* **7** 256–269. (doi:10.1038/nrc2090)
- Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M & Marini FC 2010 Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. *Cancer Gene Therapy* **17** 289–297. (doi:10.1038/cgt.2009.67)
- Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB & Isaacs JT 2003 Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. *Journal of the National Cancer Institute* **95** 990–1000. (doi:10.1093/jnci/95.13.990)
- De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A & Tubaro A 2011 The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. *European Urology* **60** 106–117. (doi:10.1016/j.eururo.2011.03.055)
- De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P *et al.* 2003 Comparison of multi-lineage cells from human adipose tissue and bone marrow. *Cells, Tissues, Organs* **174** 101–109. (doi:10.1159/000071150)
- Detante O, Moisan A, Dimastromatteo J, Richard MJ, Riou L, Grillon E, Barbier E, Desruet MD, De Fraipont F, Segebarth C *et al.* 2009 Intravenous administration of 99mTc-HMPAO-labeled human mesenchymal stem cells after stroke: *in vivo* imaging and biodistribution. *Cell Transplantation* **18** 1369–1379. (doi:10.3727/096368909X474230)
- Devine SM, Cobbs C, Jennings M, Bartholomew A & Hoffman R 2003 Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. *Blood* **101** 2999–3001. (doi:10.1182/blood-2002-06-1830)
- Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F, Cantos C, Jorgensen C & Noel D 2007 Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. *Stem Cells* **25** 2025–2032. (doi:10.1634/stemcells.2006-0548)
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D & Horwitz E 2006 Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy* **8** 315–317. (doi:10.1080/14653240600855905)
- Duan X, Guan H, Cao Y & Kleiner ES 2009 Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. *Cancer* **115** 13–22. (doi:10.1002/cncr.24013)
- van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, Weissleder R & Shah K 2010 Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. *Oncogene* **29** 3185–3195. (doi:10.1038/onc.2010.75)
- Eliopoulos N, Stagg J, Lejeune L, Pommey S & Galipeau J 2005 Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. *Blood* **106** 4057–4065. (doi:10.1182/blood-2005-03-1004)
- Elzaouk L, Moelling K & Pavlovic J 2006 Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model. *Experimental Dermatology* **15** 865–874. (doi:10.1111/j.1600-0625.2006.00479.x)
- English K & Mahon BP 2011 Allogeneic mesenchymal stem cells: agents of immune modulation. *Journal of Cellular Biochemistry* **112** 1963–1968. (doi:10.1002/jcb.23119)
- English K, Barry FP, Field-Corbett CP & Mahon BP 2007 IFN- γ and TNF- α differentially regulate immunomodulation by murine mesenchymal stem cells. *Immunology Letters* **110** 91–100. (doi:10.1016/j.imlet.2007.04.001)
- Franco OE, Shaw AK, Strand DW & Hayward SW 2010 Cancer associated fibroblasts in cancer pathogenesis. *Seminars in Cell & Developmental Biology* **21** 33–39. (doi:10.1016/j.semcdb.2009.10.010)
- Friedenstein AJ, Chailakhjan RK & Lalykina KS 1970 The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell and Tissue Kinetics* **3** 393–403. (doi:10.1111/j.1365-2184.1970.tb00347.x)
- Friedenstein AJ, Gorska JA & Kulagina NN 1976 Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Experimental Hematology* **4** 267–274.
- Fritz V, Noel D, Bouquet C, Opolon P, Voide R, Apparailly F, Louis-Plence P, Bouffi C, Drissi H, Xie C *et al.* 2008 Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. *Stem Cells* **26** 2981–2990. (doi:10.1634/stemcells.2008-0139)
- Fritz V, Brondello JM, Gordeladze JO, Reseland JE, Bony C, Yssel H, Noel D & Jorgensen C 2011 Bone-metastatic prostate carcinoma favors mesenchymal stem cell differentiation toward osteoblasts and reduces their osteoclastogenic potential. *Journal of Cellular Biochemistry* **112** 3234–3245. (doi:10.1002/jcb.23258)
- Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB & Pavlovich CP 2010 Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. *Prostate* **70** 473–481. (doi:10.1002/pros.21081)
- Gao J, Dennis JE, Muzic RF, Lundberg M & Caplan AI 2001 The dynamic *in vivo* distribution of bone marrow-derived mesenchymal stem cells after infusion. *Cells, Tissues, Organs* **169** 12–20. (doi:10.1159/000047856)
- Gao P, Ding Q, Wu Z, Jiang H & Fang Z 2010 Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. *Cancer Letters* **290** 157–166. (doi:10.1016/j.canlet.2009.08.031)
- Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J & de la Fuente R 2010 Pitfalls in spontaneous *in vitro* transformation of human mesenchymal stem cells. *Experimental Cell Research* **316** 1648–1650. (doi:10.1016/j.yexcr.2010.02.016)
- Garcia-Gomez I, Elvira G, Zapata AG, Lamana ML, Ramirez M, Castro JG, Arranz MG, Vicente A, Bueren J & Garcia-Olmo D 2010 Mesenchymal stem cells: biological properties and clinical applications. *Expert Opinion on Biological Therapy* **10** 1453–1468. (doi:10.1517/14712598.2010.519333)
- Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L & Chiarugi P 2010 Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. *Cancer Research* **70** 6945–6956. (doi:10.1158/0008-5472.CAN-10-0785)

- Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazucchi M, Barti-Juhasz H *et al.* 2010 Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. *Cancer Research* **70** 3718–3729. (doi:10.1158/0008-5472.CAN-09-1865)
- Gunnarsson S, Bexell D, Svensson A, Siesjo P, Darabi A & Bengzon J 2010 Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFN γ -transduced tumor cell immunotherapy of experimental glioma. *Journal of Neuroimmunology* **218** 140–144. (doi:10.1016/j.jneuroim.2009.10.017)
- Hanahan D & Weinberg RA 2011 Hallmarks of cancer: the next generation. *Cell* **144** 646–674. (doi:10.1016/j.cell.2011.02.013)
- Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS *et al.* 2009 A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. *Journal of the American College of Cardiology* **54** 2277–2286. (doi:10.1016/j.jacc.2009.06.055)
- Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA *et al.* 2012 Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. *Journal of the American Medical Association* **308** 2369–2379. (doi:10.1001/jama.2012.25321)
- Hermann A, List C, Habisch HJ, Vukicevic V, Ehrhart-Bornstein M, Brenner R, Bernstein P, Fickert S & Storch A 2010 Age-dependent neuroectodermal differentiation capacity of human mesenchymal stromal cells: limitations for autologous cell replacement strategies. *Cytotherapy* **12** 17–30. (doi:10.3109/14653240903313941)
- Hirschi KK & D'Amore PA 1996 Pericytes in the microvasculature. *Cardiovascular Research* **32** 687–698. (doi:10.1016/S0008-6363(96)00063-6)
- Ho AD, Wagner W & Franke W 2008 Heterogeneity of mesenchymal stromal cell preparations. *Cytotherapy* **10** 320–330. (doi:10.1080/14653240802217011)
- Hofstetter CP, Schwarz EJ, Hess D, Widenfalk J, El Manira A, Prockop DJ & Olson L 2002 Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. *PNAS* **99** 2199–2204. (doi:10.1073/pnas.042678299)
- Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, Deans RJ, Krause DS & Keating A 2005 Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* **7** 393–395. (doi:10.1080/14653240500319234)
- Huang JI, Kazmi N, Durbhakula MM, Hering TM, Yoo JU & Johnstone B 2005 Chondrogenic potential of progenitor cells derived from human bone marrow and adipose tissue: a patient-matched comparison. *Journal of Orthopaedic Research* **23** 1383–1389.
- Huang XP, Sun Z, Miyagi Y, McDonald Kinkaid H, Zhang L, Weisel RD & Li RK 2010 Differentiation of allogeneic mesenchymal stem cells induces immunogenicity and limits their long-term benefits for myocardial repair. *Circulation* **122** 2419–2429. (doi:10.1161/CIRCULATIONAHA.110.955971)
- Huang YF, Chen MJ, Wu MH & Hung SC 2013 The use of hypoxic cultured mesenchymal stem cell for oncolytic virus therapy. *Cancer Gene Therapy* **20** 308–316. (doi:10.1038/cgt.2013.22)
- Iso Y, Spees JL, Serrano C, Bakondi B, Pochampally R, Song YH, Sobel BE, Delafontaine P & Prockop DJ 2007 Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. *Biochemical and Biophysical Research Communications* **354** 700–706. (doi:10.1016/j.bbrc.2007.01.045)
- Jackson CM, Flies DB, Mosse CA, Parwani A, Hipkiss EL & Drake CG 2012 Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice. *Prostate* **73** 651–656. (doi:10.1002/pros.22606)
- Jansen BJ, Gilissen C, Roelofs H, Schaap-Oziemlak A, Veltman JA, Raymakers RA, Jansen JH, Kogler G, Figdor CG, Torensma R *et al.* 2010 Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. *Stem Cells and Development* **19** 481–490. (doi:10.1089/scd.2009.0288)
- Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S & Han ZC 2011 Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. *Frontiers of Medicine* **5** 94–100. (doi:10.1007/s11684-011-0116-z)
- Jung Y, Kim JK, Shiozawa Y, Wang J, Mishra A, Joseph J, Berry JE, McGee S, Lee E, Sun H *et al.* 2013 Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. *Nature Communications* **4** 1795. (doi:10.1038/ncomms2766)
- Kalluri R & Zeisberg M 2006 Fibroblasts in cancer. *Nature Reviews. Cancer* **6** 392–401. (doi:10.1038/nrc1877)
- Kanehira M, Xin H, Hoshino K, Maemondo M, Mizuguchi H, Hayakawa T, Matsumoto K, Nakamura T, Nukiwa T & Saijo Y 2007 Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. *Cancer Gene Therapy* **14** 894–903. (doi:10.1038/sj.cgt.7701079)
- Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R & Weinberg RA 2007 Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. *Nature* **449** 557–563. (doi:10.1038/nature06188)
- Kassis I, Zangi L, Rivkin R, Levinsky L, Samuel S, Marx G & Gorodetsky R 2006 Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads. *Bone Marrow Transplantation* **37** 967–976. (doi:10.1038/sj.bmt.1705358)
- Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G *et al.* 2006 Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. *Journal of Experimental Medicine* **203** 1235–1247. (doi:10.1084/jem.20051921)
- Kidd S, Caldwell L, Dietrich M, Samudio I, Spaeth EL, Watson K, Shi Y, Abbruzzese J, Konopleva M, Andreeff M *et al.* 2010 Mesenchymal stromal cells alone or expressing interferon- β suppress pancreatic tumors *in vivo*, an effect countered by anti-inflammatory treatment. *Cytotherapy* **12** 615–625. (doi:10.3109/14653241003631815)
- Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M & Marini FC 2012 Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. *PLoS ONE* **7** e30563. (doi:10.1371/journal.pone.0030563)
- Klopp AH, Gupta A, Spaeth E, Andreeff M & Marini F III 2011 Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? *Stem Cells* **29** 11–19. (doi:10.1002/stem.559)
- Knoop K, Kolokythas M, Klutz K, Willhauck MJ, Wunderlich N, Draganovici D, Zach C, Gildehaus FJ, Boning G, Goke B *et al.* 2011 Image-guided, tumor stroma-targeted ^{131}I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. *Molecular Therapy* **19** 1704–1713. (doi:10.1038/mt.2011.93)
- Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT & Pereboeva L 2006 Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. *Molecular Cancer Therapeutics* **5** 755–766. (doi:10.1158/1535-7163.MCT-05-0334)
- Kramer G, Mitteregger D & Marberger M 2007 Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? *European Urology* **51** 1202–1216. (doi:10.1016/j.eururo.2006.12.011)
- Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E & Dazzi F 2003 Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood* **101** 3722–3729. (doi:10.1182/blood-2002-07-2104)
- Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F *et al.* 2006 Role for interferon- γ in the immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells* **24** 386–398. (doi:10.1634/stemcells.2005-0008)
- Krampera M, Marconi S, Pasini A, Galie M, Rigotti G, Mosna F, Tinelli M, Lovato L, Anghileri E, Andreini A *et al.* 2007 Induction of neural-like differentiation in human mesenchymal stem cells derived from bone

- marrow, fat, spleen and thymus. *Bone* **40** 382–390. (doi:10.1016/j.bone.2006.09.006)
- Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW & Matthay MA 2010 Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* **28** 2229–2238. (doi:10.1002/stem.544)
- Kucerova L, Altanerova V, Matuskova M, Tyciakova S & Altaner C 2007 Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. *Cancer Research* **67** 6304–6313. (doi:10.1158/0008-5472.CAN-06-4024)
- Kucerova L, Matuskova M, Pastorakova A, Tyciakova S, Jakubikova J, Bohovic R, Altanerova V & Altaner C 2008 Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. *Journal of Gene Medicine* **10** 1071–1082. (doi:10.1002/jgm.1239)
- La Gruta NL, Kedzierska K, Stambas J & Doherty PC 2007 A question of self-preservation: immunopathology in influenza virus infection. *Immunology and Cell Biology* **85** 85–92. (doi:10.1038/sj.icb.7100026)
- Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J & Stewart DJ 2012 Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. *PLoS ONE* **7** e47559. (doi:10.1371/journal.pone.0047559)
- Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, Wang Z, Liao H, Toews GB, Krebsbach PH *et al.* 2007 Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. *Journal of Clinical Investigation* **117** 989–996. (doi:10.1172/JCI29713)
- Lanzoni G, Alviano F, Marchionni C, Bonsi L, Costa R, Foroni L, Roda G, Belluzzi A, Caponi A, Ricci F *et al.* 2009 Isolation of stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease. *Cytotherapy* **11** 1020–1031. (doi:10.3109/14653240903253840)
- Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW *et al.* 2005 Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. *Biology of Blood and Marrow Transplantation* **11** 389–398. (doi:10.1016/j.bbmt.2005.02.001)
- Le Blanc K, Tammik C, Rosendahl K, Zetterberg E & Ringden O 2003a HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Experimental Hematology* **31** 890–896. (doi:10.1016/S0301-472X(03)00110-3)
- Le Blanc K, Tammik L, Sundberg B, Haynesworth SE & Ringden O 2003b Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. *Scandinavian Journal of Immunology* **57** 11–20. (doi:10.1046/j.1365-3083.2003.01176.x)
- Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M & Ringden O 2004 Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* **363** 1439–1441. (doi:10.1016/S0140-6736(04)16104-7)
- Le Blanc K, Frasson F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M *et al.* 2008 Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* **371** 1579–1586. (doi:10.1016/S0140-6736(08)60690-X)
- Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, Semprun-Prieto L, Delafontaine P & Prockop DJ 2009 Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. *Cell Stem Cell* **5** 54–63. (doi:10.1016/j.stem.2009.05.003)
- Lee CH, Shah B, Moiola EK & Mao JJ 2010 CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. *Journal of Clinical Investigation* **120** 3340–3349. (doi:10.1172/JCI43230)
- Lee MJ, Heo SC, Shin SH, Kwon YW, Do EK, Suh DS, Yoon MS & Kim JH 2013 Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and Betaig-h3. *International Journal of Biochemistry & Cell Biology* **45** 1869–1877. (doi:10.1016/j.biocel.2013.05.027)
- Li Y & Lin F 2012 Mesenchymal stem cells are injured by complement after their contact with serum. *Blood* **120** 3436–3443. (doi:10.1182/blood-2012-03-420612)
- Li X, Sterling JA, Fan KH, Vessella RL, Shyr Y, Hayward SW, Matrisian LM & Bhowmick NA 2012 Loss of TGF- β responsiveness in prostate stromal cells alters chemokine levels and facilitates the development of mixed osteoblastic/osteolytic bone lesions. *Molecular Cancer Research* **10** 494–503. (doi:10.1158/1541-7786.MCR-11-0506)
- Li X, Wang D, Liang J, Zhang H & Sun L 2013 Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. *Bone Marrow Transplantation* **48** 544–550. (doi:10.1038/bmt.2012.184)
- Lin VK, Wang SY, Vazquez DV, Xu C, Zhang S & Tang L 2007 Prostatic stromal cells derived from benign prostatic hyperplasia specimens possess stem cell like property. *Prostate* **67** 1265–1276. (doi:10.1002/pros.20599)
- Lin G, Yang R, Banie L, Wang G, Ning H, Li LC, Lue TF & Lin CS 2010 Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. *Prostate* **70** 1066–1073. (doi:10.1002/pros.21140)
- Lin P, Lin Y, Lennon DP, Correa D, Schluchter M & Caplan AI 2012 Efficient lentiviral transduction of human mesenchymal stem cells that preserves proliferation and differentiation capabilities. *Stem Cells Translational Medicine* **1** 886–897. (doi:10.5966/sctm.2012-0086)
- Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, Mazzinghi B, Maggi L, Pasini A, Lisi V *et al.* 2008 Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. *Stem Cells* **26** 279–289. (doi:10.1634/stemcells.2007-0454)
- Liu AY, Roudier MP & True LD 2004 Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. *American Journal of Pathology* **165** 1543–1556. (doi:10.1016/S0002-9440(10)63412-8)
- Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ & Cao T 2006 The immunogenicity and immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. *Journal of Immunology* **176** 2864–2871.
- Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, Russell SJ, Dietz AB & Peng KW 2009 Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. *Clinical Cancer Research* **15** 7246–7255. (doi:10.1158/1078-0432.CCR-09-1292)
- Mishra PJ, Humeniuk R, Medina DJ, Alexe G, Mesirov JP, Ganesan S, Glod JW & Banerjee D 2008 Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. *Cancer Research* **68** 4331–4339. (doi:10.1158/0008-5472.CAN-08-0943)
- Mishra PJ, Glod JW & Banerjee D 2009 Mesenchymal stem cells: flip side of the coin. *Cancer Research* **69** 1255–1258. (doi:10.1158/0008-5472.CAN-08-3562)
- Morikawa S, Mabuchi Y, Niibe K, Suzuki S, Nagoshi N, Sunabori T, Shimmura S, Nagai Y, Nakagawa T, Okano H *et al.* 2009 Development of mesenchymal stem cells partially originate from the neural crest. *Biochemical and Biophysical Research Communications* **379** 1114–1119. (doi:10.1016/j.bbrc.2009.01.031)
- Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R & Le Blanc K 2011 The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. *Blood* **117** 4826–4835. (doi:10.1182/blood-2010-12-324038)
- Musina RA, Bekchanova ES, Belyavskii AV & Sukhikh GT 2006 Differentiation potential of mesenchymal stem cells of different origin. *Bulletin of Experimental Biology and Medicine* **141** 147–151. (doi:10.1007/s10517-006-0115-2)

- Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, Bizen A, Honmou O, Niitsu Y & Hamada H 2004 Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. *Gene Therapy* **11** 1155–1164. (doi:10.1038/sj.gt.3302276)
- Nakashima H, Kaur B & Chiocca EA 2010 Directing systemic oncolytic viral delivery to tumors via carrier cells. *Cytokine & Growth Factor Reviews* **21** 119–126. (doi:10.1016/j.cytogfr.2010.02.004)
- Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R & Fibbe WE 2006 Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. *Blood* **108** 2114–2120. (doi:10.1182/blood-2005-11-011650)
- Nelson WG, De Marzo AM & Isaacs WB 2003 Prostate cancer. *New England Journal of Medicine* **349** 366–381. (doi:10.1056/NEJMra021562)
- Newman RE, Yoo D, LeRoux MA & Danilkovitch-Miagkova A 2009 Treatment of inflammatory diseases with mesenchymal stem cells. *Inflammation & Allergy Drug Targets* **8** 110–123. (doi:10.2174/187152809788462635)
- Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC & Rittmaster RS 2008 The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. *European Urology* **54** 1379–1384. (doi:10.1016/j.eururo.2007.11.026)
- Niemeyer P, Vohrer J, Schmal H, Kasten P, Fellenberg J, Suedkamp NP & Mehlhorn AT 2008 Survival of human mesenchymal stromal cells from bone marrow and adipose tissue after xenogenic transplantation in immunocompetent mice. *Cytotherapy* **10** 784–795. (doi:10.1080/14653240802419302)
- Niess H, Bao Q, Conrad C, Zischek C, Notohamiprodjo M, Schwab F, Schwarz B, Huss R, Jauch KW, Nelson PJ et al. 2011 Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. *Annals of Surgery* **254** 767–774; discussion 774–765. (doi:10.1097/SLA.0b013e3182368c4f)
- Noel D, Caton D, Roche S, Bony C, Lehmann S, Casteilla L, Jorgensen C & Cousin B 2008 Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. *Experimental Cell Research* **314** 1575–1584. (doi:10.1016/j.yexcr.2007.12.022)
- Nombela-Arrieta C, Ritz J & Silberstein LE 2011 The elusive nature and function of mesenchymal stem cells. *Nature Reviews. Molecular Cell Biology* **12** 126–131. (doi:10.1038/nrm3049)
- Ohlsson LB, Varas L, Kjellman C, Edvardsen K & Lindvall M 2003 Mesenchymal progenitor cell-mediated inhibition of tumor growth *in vivo* and *in vitro* in gelatin matrix. *Experimental and Molecular Pathology* **75** 248–255. (doi:10.1016/j.yexmp.2003.06.001)
- Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD & Cunha GR 1999 Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. *Cancer Research* **59** 5002–5011.
- Orimo A & Weinberg RA 2006 Stromal fibroblasts in cancer: a novel tumor-promoting cell type. *Cell Cycle* **5** 1597–1601. (doi:10.4161/cc.5.15.3112)
- Osiris Therapeutics I 2012 World's First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal. Ed E Elchun. Columbia, MD. (available at: http://investor.osiris.com/release_detail.cfm?ReleaseID=674658)
- Osterholm MT 2005 Preparing for the next pandemic. *New England Journal of Medicine* **352** 1839–1842. (doi:10.1056/NEJMp058068)
- Pachon-Pena G, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA & Gimble JM 2011 Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. *Journal of Cellular Physiology* **226** 843–851. (doi:10.1002/jcp.22408)
- Panepucci RA, Siufl JL, Silva WA Jr, Proto-Siquiera R, Neder L, Orellana M, Rocha V, Covas DT & Zago MA 2004 Comparison of gene expression of umbilical cord vein and bone marrow-derived mesenchymal stem cells. *Stem Cells* **22** 1263–1278. (doi:10.1634/stemcells.2004-0024)
- Park HW, Shin JS & Kim CW 2007 Proteome of mesenchymal stem cells. *Proteomics* **7** 2881–2894. (doi:10.1002/pmic.200700089)
- Paunescu V, Bojin FM, Tatu CA, Gavriluciu OI, Rosca A, Gruia AT, Tanasie G, Bunu C, Crisnic D, Gherghiceanu M et al. 2011 Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. *Journal of Cellular and Molecular Medicine* **15** 635–646. (doi:10.1111/j.1582-4934.2010.01044.x)
- Pessina A, Bonomi A, Cocce V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Vigano L, Locatelli A et al. 2011 Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. *PLoS ONE* **6** e28321. (doi:10.1371/journal.pone.0028321)
- Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rouso-Noori L, Zanin-Zhorov A, Cohen S, Cohen IR & Zipori D 2007 Toll-like receptors and their ligands control mesenchymal stem cell functions. *Blood* **109** 1422–1432. (doi:10.1182/blood-2006-06-028704)
- Pevsner-Fischer M, Levin S & Zipori D 2011 The origins of mesenchymal stromal cell heterogeneity. *Stem Cell Reviews* **7** 560–568. (doi:10.1007/s12015-011-9229-7)
- Phinney DG & Prockop DJ 2007 Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair – current views. *Stem Cells* **25** 2896–2902. (doi:10.1634/stemcells.2007-0637)
- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S & Marshak DR 1999 Multilineage potential of adult human mesenchymal stem cells. *Science* **284** 143–147. (doi:10.1126/science.284.5411.143)
- Placencio VR, Li X, Sherrill TP, Fritz G & Bhowmick NA 2010 Bone marrow derived mesenchymal stem cells incorporate into the prostate during regrowth. *PLoS ONE* **5** e12920. (doi:10.1371/journal.pone.0012920)
- Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ & Alt EU 2010 Adipose tissue-derived stem cells promote prostate tumor growth. *Prostate* **70** 1709–1715. (doi:10.1002/pros.21206)
- Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R & Kurtzberg J 2011 Efficacy and safety of *ex vivo* cultured adult human mesenchymal stem cells (Prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. *Biology of Blood and Marrow Transplantation* **17** 534–541. (doi:10.1016/j.bbmt.2010.04.014)
- PRNewswire 2011 Positive Results from Phase 2 Trial of Mesoblast's Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting. Orlando, FL and Melbourne, Australia. (available at: www.prnewswire.com/news-releases/positive-results-from-phase-2-trial-of-mesoblasts-adult-stem-cell-therapy-presented-at-the-american-heart-association-annual-meeting-133835958.html)
- Prockop DJ 2007 "Stemness", does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs). *Clinical Pharmacology and Therapeutics* **82** 241–243. (doi:10.1038/sj.clpt.6100313)
- Prockop DJ 2013 Two negative feedback loops place mesenchymal stem/stromal cells (MSCs) at the center of early regulators of inflammation. *Stem Cells* [in press]. (doi:10.1002/stem.1400)
- Prockop DJ & Oh JY 2012 Mesenchymal stem/stromal cells (MSCs): role as guardians of inflammation. *Molecular Therapy* **20** 14–20. (doi:10.1038/mt.2011.211)
- Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L & Zhang X 2008 Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. *Cell Research* **18** 500–507. (doi:10.1038/cr.2008.40)
- Rada T, Reis RL & Gomes ME 2011 Distinct stem cells subpopulations isolated from human adipose tissue exhibit different chondrogenic and osteogenic differentiation potential. *Stem Cell Reviews* **7** 64–76. (doi:10.1007/s12015-010-9147-0)
- Rasmuson I, Ringden O, Sundberg B & Le Blanc K 2005 Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. *Experimental Cell Research* **305** 33–41. (doi:10.1016/j.yexcr.2004.12.013)
- Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD & Ponnazhagan S 2008a Cancer gene therapy using mesenchymal stem

- cells expressing interferon- β in a mouse prostate cancer lung metastasis model. *Gene Therapy* **15** 1446–1453. (doi:10.1038/gt.2008.101)
- Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC & Shi Y 2008b Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. *Cell Stem Cell* **2** 141–150. (doi:10.1016/j.stem.2007.11.014)
- Sakaguchi Y, Sekiya I, Yagishita K & Muneta T 2005 Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis and Rheumatism* **52** 2521–2529. (doi:10.1002/art.21212)
- Santamaria-Martinez A, Barquinero J, Barbosa-Desongles A, Hurtado A, Pinos T, Seoane J, Poupon MF, Morote J, Reventos J & Munell F 2009 Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. *Experimental Cell Research* **315** 3004–3013. (doi:10.1016/j.yexcr.2009.05.007)
- Sarkar D, Spencer JA, Phillips JA, Zhao W, Schafer S, Spelke DP, Mortensen LJ, Ruiz JP, Vemula PK, Sridharan R et al. 2011 Engineered cell homing. *Blood* **118** e184–e191. (doi:10.1182/blood-2010-10-311464)
- Sfanos KS & De Marzo AM 2012 Prostate cancer and inflammation: the evidence. *Histopathology* **60** 199–215. (doi:10.1111/j.1365-2559.2011.04033.x)
- Shah K 2012 Mesenchymal stem cells engineered for cancer therapy. *Advanced Drug Delivery Reviews* **64** 739–748. (doi:10.1016/j.addr.2011.06.010)
- Shimoda M, Mellody KT & Orimo A 2010 Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. *Seminars in Cell & Developmental Biology* **21** 19–25. (doi:10.1016/j.semcdb.2009.10.002)
- da Silva Meirelles L, Chagastelles PC & Nardi NB 2006 Mesenchymal stem cells reside in virtually all post-natal organs and tissues. *Journal of Cell Science* **119** 2204–2213. (doi:10.1242/jcs.02932)
- Song C, Xiang J, Tang J, Hirst DG, Zhou J, Chan KM & Li G 2011 Thymidine kinase gene modified bone marrow mesenchymal stem cells as vehicles for antitumor therapy. *Human Gene Therapy* **22** 439–449. (doi:10.1089/hum.2010.116)
- Spaeth E, Klopp A, Dembinski J, Andreeff M & Marini F 2008 Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. *Gene Therapy* **15** 730–738. (doi:10.1038/gt.2008.39)
- Spaggiari GM, Capobianco A, Becchetti S, Mingari MC & Moretta L 2006 Mesenchymal stem cell–natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. *Blood* **107** 1484–1490. (doi:10.1182/blood-2005-07-2775)
- Stagg J, Pommey S, Eliopoulos N & Galipeau J 2006 Interferon- γ -stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. *Blood* **107** 2570–2577. (doi:10.1182/blood-2005-07-2793)
- Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT et al. 2007 Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. *Breast Cancer Research and Treatment* **105** 157–167. (doi:10.1007/s10549-006-9449-8)
- Strioga M, Viswanathan S, Darinskas A, Slaby O & Michalek J 2012 Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells *Stem Cells and Development* **21** 2724–2752. (doi:10.1089/scd.2011.0722)
- Studený M, Marini FC, Champlin RE, Zompetta C, Fidler IJ & Andreeff M 2002 Bone marrow-derived mesenchymal stem cells as vehicles for interferon- β delivery into tumors. *Cancer Research* **62** 3603–3608.
- Studený M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE & Andreeff M 2004 Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. *Journal of the National Cancer Institute* **96** 1593–1603. (doi:10.1093/jnci/djh299)
- Sun YX, Wang J, Shelburne CE, Lopatin DE, Chinnaiyan AM, Rubin MA, Pienta KJ & Taichman RS 2003 Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) *in vivo*. *Journal of Cellular Biochemistry* **89** 462–473. (doi:10.1002/jcb.10522)
- Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L & Nelson PS 2012 Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. *Nature Medicine* **18** 1359–1368. (doi:10.1038/nm.2890)
- Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C & Le Blanc K 2007 No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. *Haematologica* **92** 1208–1215. (doi:10.3324/haematol.11446)
- Takashima Y, Era T, Nakao K, Kondo S, Kasuga M, Smith AG & Nishikawa S 2007 Neuroepithelial cells supply an initial transient wave of MSC differentiation. *Cell* **129** 1377–1388. (doi:10.1016/j.cell.2007.04.028)
- Technau A, Froelich K, Hagen R & Kleinsasser N 2011 Adipose tissue-derived stem cells show both immunogenic and immunosuppressive properties after chondrogenic differentiation. *Cytotherapy* **13** 310–317. (doi:10.3109/14653249.2010.504769)
- Torsvik A, Rosland GV, Svendsen A, Molven A, Immervoll H, McCormack E, Lønning PE, Primon M, Sobala E, Tonn JC et al. 2010 Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track – letter. *Cancer Research* **70** 6393–6396. (doi:10.1158/0008-5472.CAN-10-1305)
- True LD, Zhang H, Ye M, Huang CY, Nelson PS, von Haller PD, Tjoelker LW, Kim JS, Qian WJ, Smith RD et al. 2010 CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. *Modern Pathology* **23** 1346–1356. (doi:10.1038/modpathol.2010.122)
- Tse WT, Pendleton JD, Beyer WM, Egalka MC & Guinan EC 2003 Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation* **75** 389–397. (doi:10.1097/01.TP.0000045055.63901.A9)
- Tu Z, Li Q, Bu H & Lin F 2010 Mesenchymal stem cells inhibit complement activation by secreting factor H. *Stem Cells and Development* **19** 1803–1809. (doi:10.1089/scd.2009.0418)
- Vaday GG, Peehl DM, Kadam PA & Lawrence DM 2006 Expression of CCL5 (RANTES) and CCR5 in prostate cancer. *Prostate* **66** 124–134. (doi:10.1002/pros.20306)
- Vodyanik MA, Yu J, Zhang X, Tian S, Stewart R, Thomson JA & Slukvin II 2010 A mesoderm-derived precursor for mesenchymal stem and endothelial cells. *Cell Stem Cell* **7** 718–729. (doi:10.1016/j.stem.2010.11.011)
- Vogel G 2010 Cell biology. To scientists' dismay, mixed-up cell lines strike again. *Science* **329** 1004. (doi:10.1126/science.329.5995.1004)
- Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W et al. 2005 Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Experimental Hematology* **33** 1402–1416. (doi:10.1016/j.exphem.2005.07.003)
- Wakitani S, Saito T & Caplan AI 1995 Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. *Muscle Nerve* **18** 1417–1426. (doi:10.1002/mus.880181212)
- Wang GX, Zhan YA, Hu HL, Wang Y & Fu B 2012 Mesenchymal stem cells modified to express interferon- β inhibit the growth of prostate cancer in a mouse model. *Journal of International Medical Research* **40** 317–327. (doi:10.1177/147323001204000132)
- Weiss DJ, Casaburi R, Flannery R, Leroux-Williams M & Tashkin DP 2013 A placebo-controlled randomized trial of mesenchymal stem cells in chronic obstructive pulmonary disease. *Chest* **143** 1590–1598. (doi:10.1378/chest.12-2094)
- Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT & Denmeade SR 2007 A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. *Journal of the National Cancer Institute* **99** 376–385. (doi:10.1093/jnci/djk065)
- Woodbury D, Schwarz EJ, Prockop DJ & Black IB 2000 Adult rat and human bone marrow stromal cells differentiate into neurons. *Journal of*

- Neuroscience Research* **61** 364–370. (doi:10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C)
- Ye H, Cheng J, Tang Y, Liu Z, Xu C, Liu Y & Sun Y 2012 Human bone marrow-derived mesenchymal stem cells produced TGF β contributes to progression and metastasis of prostate cancer. *Cancer Investigation* **30** 513–518. (doi:10.3109/07357907.2012.692171)
- Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X, Kim SH, Lim YC, Nam DH, You S *et al.* 2011 hMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence. *Molecular Therapy* **19** 1161–1169. (doi:10.1038/mt.2011.28)
- Zhang W, Walboomers XF, Shi S, Fan M & Jansen JA 2006 Multilineage differentiation potential of stem cells derived from human dental pulp after cryopreservation. *Tissue Engineering* **12** 2813–2823. (doi:10.1089/ten.2006.12.2813)
- Zhang X, Xu W, Qian H, Zhu W & Zhang R 2011 Mesenchymal stem cells modified to express lentivirus TNF- α Tumstatin(45–132) inhibit the growth of prostate cancer. *Journal of Cellular and Molecular Medicine* **15** 433–444. (doi:10.1111/j.1582-4934.2009.00920.x)
- Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, Chen L, Lv S, Li Y, Yu S *et al.* 2012 Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. *Journal of Gastroenterology and Hepatology* **27** (Suppl 2) 112–120. (doi:10.1111/j.1440-1746.2011.07024.x)
- Zhao H & Peehl DM 2009 Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. *Prostate* **69** 991–1000. (doi:10.1002/pros.20946)
- Zhukareva V, Obrocka M, Houle JD, Fischer I & Neuhuber B 2010 Secretion profile of human bone marrow stromal cells: donor variability and response to inflammatory stimuli. *Cytokine* **50** 317–321. (doi:10.1016/j.cyt.2010.01.004)
- Zimmet JM & Hare JM 2005 Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. *Basic Research Cardiology* **100** 471–481. (doi:10.1007/s00395-005-0553-4)
- Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, Nelson PJ & Bruns C 2009 Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. *Annals of Surgery* **250** 747–753. (doi:10.1097/SLA.0b013e3181bd62d0)
- Zolochovska O, Yu G, Gimble JM & Figueiredo ML 2012 Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth. *Stem Cells and Development* **21** 1112–1123. (doi:10.1089/scd.2011.0247)
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P & Hedrick MH 2002 Human adipose tissue is a source of multipotent stem cells. *Molecular Biology of the Cell* **13** 4279–4295. (doi:10.1091/mbc.E02-02-0105)

Received in final form 10 July 2013

Accepted 25 July 2013